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ABSTRACT 
 
SODSI WIROJCHANASAK: Role of NFκB p65 in osteogenesis through  
 osteoblast regulation 
(Under the direction of Professor Lyndon F. Cooper) 
 
 
 
Inflammation affects bone repair and strongly impacts bone regeneration 
therapy. The transcription factor NFκB mediates inflammatory responses which exert 
regulatory effects on bone homeostasis. Concepts regarding the effect of inflammation 
on osteogenesis during bone development remain elusive. The current study 
investigated the influence of NFκB on osteogenesis through osteoblast regulation in 
vivo using a Cre-LoxP recombination strategy. Mice with p65 haploinsufficiency 
targeting osteoprogenitors were generated and the phenotypes were characterized. The 
mice lacking one p65 allele in osteogenic cells displayed reduced skeletal dimension, 
less bone mineralization and altered bone structure. Cellular assays provided evidence 
that reduced NFκB activities due to p65 haploinsufficiency resulted in decreased 
differentiation and elevated apoptosis in the osteogenic cells. Increased in situ 
apoptosis in bones from the mutant mice confirmed the protective role of NFκB in 
osteogenic cell survival. Lack of one p65 allele attenuated osteogenic potential of 
mesenchymal stem cells derived from the mutant mice. The heterotopic bone 
formation  approach  using  BMP2 was employed to assess bone formation potential in 
 iii 
the mice with p65 haploinsufficiency in osteoprogenitors. The p65 haploinsufficienty 
mice showed less newly formed bone in the BMP2-induced bone regeneration process 
in compared with the controls due to reduced osteoblast differentiation. In conclusion, 
NFκB modulates osteoblastic activities. Diminution of NFκB activities in 
osteoprogenitors retards bone development which alters skeletal size and bone 
architecture. Decreased osteoblastic differentiation and increased apoptosis in the p65 
haploinsufficient osteogenic cells indicate that there are multiple levels which NFκB 
acts in control of bone formation. 
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CHAPTER 1 
 
INTRODUCTION 
 
Bone: function and health impact from bone disorders 
Bone is a dynamic mineralized organ that continually remodels via the 
turnover of extracellular and cellular components, as regulated by coordinated 
activities of bone forming cells (osteoblasts) and bone resorbing cells (osteoclasts). 
Bone by itself, or in concert with cartilage, is a principle structure of the skeletal 
system which serves a major function in mechanical support. Additionally, the 
functions of bone involve a) protection of vital organs including brain, heart, lung, and 
bone marrow, b) locomotion with muscle and tendon attachment, and c) reservoirs for 
calcium and phosphate mineral contents (Cohen, 2006).  
Dysregulation of osteoblasts and/or osteoclasts negatively affects bone 
structure which leads to disturbance of skeletal functions. Several diseases derived 
from imbalanced bone homeostasis such as osteoporosis and Paget’s disease of bone 
have been global health problems. Osteoporosis is a metabolic bone disease that leads 
to reduced bone mineral density as a consequence from excessive bone resorption and 
diminished bone formation. Paget’s disease of bone is a localized bone disorder with 
enlarged   but  weak  bone  affected  by  excessive   bone  resorption   from  overactive 
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osteoclasts and accelerated bone formation in a disorganized pattern from osteoblasts. 
In the United States, osteoporosis is one major public health problem that affects more 
than 44 million American people. Paget’s disease of bone is the second most common 
bone disease with approximately one million patients having misshapen and/or 
fracture of the affected bones (NIAMS, 2011). In each year, over 1.5 million 
osteoporotic patients suffer from bone fractures and millions more are at risk. 
Compromised bone formation in the osteoporotic patients causes problems for 
orthopedic and bone regenerative treatment outcomes (Cornell et al., 2003; LaPorte et 
al., 2008). The failure of these treatments is a consequence of decreased amount of 
bone tissues and active bone forming cells (Perrini et al., 2008). Thus, it is compelling 
for researchers to clarify pathways that enhance bone formation in order to succeed in 
the recovery of the bone functions.   
Another problematic bone disorder arises from critical-size bone defects from 
congenital anomalies, ablative surgery, fracture or injuries. The bone defect size over a 
critical limit results in the impairment of the skeletal functions according to 
incomplete bone reconstruction. The critical-size bone defect exceeds the natural 
healing potential of body which leads to fibrous tissue formation rather than new bone 
formation in the defect. Although bone tissues contain regenerative capacity, 
compromised conditions from the impaired functions of bone cells or from the critical-
size defects can restrain bone reconstruction outcome. Successful treatments of the 
compromised bone defects by conventional or advanced therapeutic modalities, like 
bone grafting and tissue engineering techniques, depends on the potential of 
osteoblasts in synthesizing sufficient bone mass to restore the bone functions (Bruder 
 3
and Fox, 1999). Manipulation of coordinating factors that favors osseous healing 
environments can improve the recruitment of osteogenic cells thus enhancing new 
bone tissue formation (Salgado et al., 2004; Ward et al., 2010). Although a number of 
the regulatory molecules of bone have been identified, there is a gap of knowledge 
regarding complex biological pathways applicable to bone regeneration. Therefore, 
deciphering the factors that influence bone formation is essential for developing 
therapeutic approaches for bone defects which will ultimately increase success rates of 
the treatments. 
Bone developmental and regeneration processes 
Osteogenesis is a process that results in the formation of bone tissues. To 
maintain physiological bone structures, osteogenesis is required for increase of bone 
mass during development and for compensation of bone loss from bone resorption or 
injuries (Katagiri and Takahashi, 2002; Zaidi, 2007). The mechanisms for 
osteogenesis occur into two different patterns. One is intramembranous ossification 
which originates from neural crest cells that form mesenchymal condensation and 
differentiate directly into osteoblasts in craniofacial bones. The other is endochondral 
ossification, a developmental process that requires cartilagenous templates before 
bone replacement in axial and limb skeletons. In the endochondral mechanism, 
mesenchymal cells first differentiate into chondroblasts to generate the cartilage 
template then develop to hypertrophic chondrocytes. The chondrocytes are 
subsequently replaced by osteoblasts which derive from the same mesenchymal cell 
origin together with vascular ingrowth (Neve et al., 2011). After bone tissues are 
formed, some osteoblasts are embedded in mineralized bone matrices and become 
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osteocytes which function in transmitting signals in response to mechanical forces 
(Jiang et al., 2007). Some osteoblasts become inactive lining cells called pericytes at 
bone surfaces as a reservoir of bone forming cells. Concurrently to the bone formation 
process, osteoclasts develop and function in remodelling bone structures into proper 
shapes and resorbing bone tissues to create bone marrow spaces (Neve et al., 2011). 
During the developmental state, the bone formation rate is higher than the bone 
resorption rate while bones in mature state require balanced functions between 
osteoblasts and osteoclasts to maintain a tissue integrity (Cohen, 2006; Datta et al., 
2008). 
The mechanisms of the bone formation during osseous healing processes are 
overlapped with those of the bone development in both intramembranous and 
endochondral ossifications (Gerstenfeld et al., 2003). The expression of the molecular 
markers of chondrogenesis and osteogenesis during bone repair corresponds to the 
markers that are presented throughout bone developmental processes (Grimes et al., 
2011). One different aspect between bone developmental and healing processes is an 
initial inflammatory reaction which is apparent in the beginning of osseous healing. 
Previous studies suggested that the initial inflammatory response plays a role in 
priming the subsequent bone regeneration process by triggering a release of enhancing 
factors for bone formation. However, chronic inflammation has an opposite effect, 
causing a failure in bone formation (Crisostomo et al., 2008; Mountziaris et al., 2011). 
Another factor that regulates the bone reparative processes is dependent on the 
mechanical environment. Non-stabilized bone fractures heal via endochondral 
ossification while stabilized bone fractures and cortical bone defects are restored 
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through intramembranous healing (Behonick et al., 2007; Lu et al., 2004). During the 
endochondral healing, granulation tissues are formed at the early inflammatory phase 
with the aggregation of growth factors and osteoblastic stimulating molecules (Itagaki 
et al., 2008). Stem cells from bone marrow and lining cells at periosteum, and cells 
from other sources are triggered by these changes of microenvironment, then migrate 
into the lesion site and differentiate into chondrogenic and osteogenic cells afterwards 
(Schindeler et al., 2008). A later stage is a reparative/regenerative period starting with 
callus formation, determined by a fibrocartilage formation at post-fracture from day 3 
to day 7 then followed by bone replacement at post-fracture day 10 to day 14. The 
newly formed tissue is finally remodeled by osteoclasts representing functional bone 
architecture (Gerstenfeld et al., 2003; Kilian et al., 2008). For intramembranous bone 
healing, bone formation is established following an inflammatory phase without 
cartilage formation from the beginning of bone regeneration until the end of bone 
remodeling phase (Thompson et al., 2002).  
In tissue engineering-induced bone regeneration, designated approaches are 
based on the principles of modulating a healing environment to be suitable for bone 
reconstruction by targeting cells, extracellular matrix, and signaling molecules 
(Cooper et al., 2001; Scheller et al., 2009). The repairing processes from bone tissue 
engineering occur in a cascade of events similar to bone fracture healing with acute 
inflammation in the beginning, followed by bone formation and bone remodeling.  For 
instance, the use of bone morphogenetic proteins 2 (BMP2)-induced bone formation 
leads to endochondral ossification according to osteoinduction potential of this growth 
factor (Hou et al., 2007).  
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Osteoblast formation and function in osteogenesis 
Osteoblasts play a central role in osteogenesis during skeletal development, 
bone homeostasis, bone repair and regeneration as these cells serve functions in bony 
structure formation and remodeling. Osteoblasts arise from mesenchymal origin and 
share a common progenitor with chondrocytes, myoblasts and adipocytes (Pittenger et 
al., 1999; Prockop et al., 2003; Song et al., 2006). During osteogenesis, osteoblasts are 
developed from mesenchymal stem cells through multiple stages from proliferation, 
differentiation, matrix maturation, and mineralization. Mesenchymal stem cells 
differentiate into osteochondro-progenitor cells which are able to transform to 
chondrogenic or osteogenic cells. These progenitor cells develop to particular 
terminally differentiated cells according to the specification of cell fate (called lineage 
commitment) via expression of specific signaling molecules during differentiation 
(Long, 2011). For osteoblastic lineage, the progenitor cells differentiate to 
proliferating pre-osteoblasts which turn into mature osteoblasts. After mature 
osteoblasts perform bone matrix production, many osteoblasts succumb to apoptosis. 
Some of these osteoblasts proceed to terminally differentiated osteocytes residing in 
calcified bone tissue. Some osteoblasts become inactive lining cells adjacent to 
periosteum and bone surface for bone turnover purpose (Neve et al., 2011).  
During osteoblast formation, a number of molecules are expressed as 
phenotypic markers of specific developmental stages of osteoblast and involve in bone 
structure establishment (Long, 2011). Increased levels of type 1 collagen, alkaline 
phosphatase (ALP) and bone sialoprotein (BSP) are considered as early markers of 
osteoblast development from proliferation to matrix maturation stages. Osteocalcin 
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(OCN) is presented during mineralization stage as a late marker for mature 
osteoblasts. In addition to bone formation, osteoblasts serve a function in osteoclast 
regulation as a part of bone remodeling control (Neve et al., 2011). Osteoblasts 
produce receptor activator of nuclear factor kappa-B ligand (RANKL), a required 
factor for osteoclast differentiation and activation. With stimulation by RANKL and 
macrophage colony stimulating factor (M-CSF), osteoclasts become mature, as 
characterized by the presence of tartrate resistant acid phosphatase (TRAP) and 
cathepsin K, and mediate bone resorption during osteogenesis and bone repair 
(Yamamoto et al., 2006). Osteoblasts also provide negative feedback control in 
osteoclast development by production of osteoprotegerin (OPG) to block RANKL-
activation of osteoclasts (Neve et al., 2011).  
Regulation of osteoblastic differentiation  
The control of osteoblastic differentiation is orchestrated by a complex array of 
environmental factors that are manifested in extracellular matrix such as cytokines, 
growth factors, and hormones. The extrinsic regulation over osteoblasts is exerted 
through cellular interaction with these extracellular elements or cell-cell interaction 
which provokes intrinsic change over aspects of cell fate involving pluripotency, 
proliferative capacity, and differentiation state (Katagiri and Takahashi, 2002). 
Intrinsic change during osteoblast differentiation requires sequential expression of 
several molecules to determine the specification of mesenchymal stem cells into 
ostoeblastic lineage (Long, 2011). The most frequently investigated osteogenic 
signaling pathway involves the expression of transcription factor RUNX2 and OSX 
which contributes to BMP2 regulation of osteoinduction and maintenance of 
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osteoblast specification during mesenchymal stem cell differentiation (Baek et al., 
2010; Ducy et al., 1999; Katagiri and Takahashi, 2002; Nakashima et al., 2002). 
BMP2 osteogenic signaling 
BMP2 belongs to a transforming growth factor beta (TGFβ) superfamily as a 
member of Bmps subfamily (Cao and Chen, 2005). Recombinant human BMP2 has 
been used clinically to promote bone formation via profound action on 
osteoblastogenesis (Boyne et al., 2005; Katayama et al., 2009). BMP2 is critical to 
embryonic development and postnatal physiology attributed to its pleiotropic function. 
Various animal models have been used to reveal the functions of BMP2. Null 
mutation of Bmp2 caused embryonic lethality in mice from day 7.5 to day 10.5 due to 
failure in cardiac development (Zhang and Bradley, 1996). Mice with conditional 
deletion of Bmp2 under control of Pair-related homeobox (Prx)-1 expression, a marker 
in axial skeletons, have retarded bone growth and spontaneous bone fracture in limb 
skeletons with impaired fracture healing at postpubertal age (Tsuji et al., 2006).  
Application of BMP2 in either soluble form or by gene delivery induce bone 
formation in both orthotropic and heterotropic locations (Hou et al., 2007; Hu et al., 
2010; Kim et al., 2011). 
BMP2 signaling of osteoblast specification is mediated through the activation 
of BMP type I and type II receptors (BMP-RI, BMP-RII) similar to other BMPs (Nohe 
et al., 2002). Upon stimulation by BMP2, there are two different signaling pathways 
depending on the oligomerization patterns of BMP receptors. In the first pathway, 
BMP2 binds to preformed receptor complex of BMP-RI and BMP-RII. This pathway 
initiates signal transduction through SMAD1/5/8 phosphorylation by BMP-RI in the 
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ligand-receptor complex. The phosphorylated SMAD1/5/8 proteins generate complex 
formation with common partners-SMAD, SMAD4 and translocate into the nucleus to 
regulate target gene transcription. One SMAD-mediated transcriptional control 
proceeds through co-activation with RUNX2 transcription factor (Afzal et al., 2005; 
Lee et al., 2000). The second pathway is signaled by BMP2 involves oligomerization 
of homomeric BMP-RI complex which subsequently recruits BMP-RII into the 
complex then activates p38 mitogen activated protein kinase (MAPK) signaling 
pathway which leads to induction of ALP activity (Nohe et al., 2002).  
RUNX2 osteogenic signaling 
Runt-related transcription factor 2 (RUNX2) is the earliest marker that 
contributes to the regulation of osteoblast specification by controlling the expression 
of osteoblastic related genes such as COL1A1, BSP, osteopontin (OPN), and OCN 
(Jang et al., 2012). Gene mutation of RUNX2 indicates its essential role in osteoblast 
and chondrocyte differentiation. RUNX2 mutation in human is associated with bone 
disorder from defect in intramembranous ossification called cleidocranial dysplasia 
which resembles bone phenotype in Runx2 haploinsufficient mice (Otto et al., 1997; 
Zhang et al., 2000). Mice devoid of Runx2 exhibit cartilaginous skeleton with defect in 
chondrocytes and lack of osteoblasts (Ducy, 2000; Komori et al., 1997; Nakashima et 
al., 2002). Overexpression of RUNX2 can provoke osteoblastic phenotype expression 
as presented by OCN and BSP in non-osteoblastic cells (Ducy et al., 1997). 
RUNX2 is a multifunctional transcription factor that interacts with a specific 
DNA binding site in promoter or enhancer regions of its target genes to induce or 
suppress transcription activity (Ducy et al., 1997). RUNX2 regulates target genes by 
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involves in chromatin remodeling, reacting at promoter regions of target genes, and 
independent signaling pathway. The temporal action of RUNX2 involves activation of 
various osteoblastic genes at specific differentiation stages and is dependent on its 
association with various co-regulatory proteins and collaborating proteins (Lian and 
Stein, 2003). An example of RUNX2 and co-regulatory protein complex is RUNX2-
SMAD regulation following BMP induction (Afzal et al., 2005). The other co-
regulatory proteins that involve in osteoblast regulation include TAZ (Cui et al., 
2003), STAT1 (Kim et al., 2003), YAP (Stein et al., 2003), and TWIST (Yousfi et al., 
2002).  
OSX osteogenic signaling 
The zinc finger-containing transcription factor OSX or the present name SP7 
appears to act downstream of RUNX2 to commit progenitor cells into osteoblastic 
differentiation (Nakashima et al., 2002). In situ hybridization of mouse embryonic 
tissues at different stages demonstrates the localization of Osx in cells associated with 
developing bones. Mice with target deletion of Osx develop normal cartilage but no 
bone formation occurs due to arrested osteoblast differentiation. Runx2 expression in 
Osx null mice showed comparable levels to wild type mice. Overexpression of Runx2 
results in Osx induction in C2C12 cells. Runx2 regulates Osx expression through 
Smad signaling pathway as Osx expression in Runx2 deficient mesenchymal cells is 
rescued by the presence of Smad1/4. In addition to the Runx2 related mechanism, Osx 
expression is regulated under Msx homeobox homologue 2 (Msx2)-independent 
pathway upon Bmp2 stimulation (Matsubara et al., 2008).  
Osx  contributes  to  osteoblast  differentiation  control  under  overlapping and 
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non-overlapping mechanisms to Runx2 function. Microarray data from C3H10T1/2 
cells reveal different gene profiles upon stimulation by Osx in compared with Runx2. 
Although both groups share several similar osteoblastic related genes such as Wnt4, 
Bglap1, Bmp7, there are a group of genes induced by Osx but not Runx2 (Matsubara 
et al., 2008). The function of Osx is directed through its transcriptional activity as 
found in regulation of type I collagen, bone sialoprotein, osteopontin, osteocalcin, and 
an osteoinductive factor Nel-like molecule1 (Nell1) (Chen et al., 2011; Harada and 
Rodan, 2003). The nuclear factor of activated T cells, cytoplasmic 1 (Nfatc1) has been 
found to promote Osx transcriptional function during osteoblast differentiation (Koga 
et al., 2005; Winslow et al., 2006). One mechanism in which Osx induces osteoblastic 
gene expression was defined by the study from osteocalcin transcriptional regulation. 
Osx binds to Ocn promoter region at Sp1/Osx binding site with the enhancement by 
Specificity protein 1 (Sp1) in increasing Osx affinity (Niger et al., 2011). However 
there are other pathways involves during osteoblast differentiation. The regulatory 
mechanism for bone formation remains to be elucidated.  
Inflammation and bone homeostasis 
Inflammation is an immediate response that occurs during injuries to eliminate 
noxious stimuli and to initiate healing/repair process. The inflammatory response is 
tightly associated with immune cells which are provoked to migrate to the lesion site. 
The detrimental effects of chronic inflammatory responses have been implicated in 
pathogenesis of several diseases relevant to the imbalance of bone formation and 
resorption such as periodontitis and rheumatoid arthritis (Makarov, 2001; Nichols et al., 
2001). Rarely is inflammation considered positively in bone formation except during 
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healing process as it represents a critical aspect of wound healing. Impaired osseous 
wound healing due to reduced osteogenic potential has been illustrated in mice with 
impaired inflammatory responses from target impairment of genes encoding 
cyclooxygenase-2, Tnfα, Il6, and Fas-ligand (Mountziaris et al., 2011). Although the 
regulatory role of inflammatory response in bone homeostasis has been studied 
perspective of bone resorption through immune cells and osteoclasts (Makarov, 2001; 
Nichols et al., 2001), little is known about direct relationship between inflammation 
and bone formation specifically in cells responsible for osteogenesis.  
NFκB pathway 
Nuclear factor κB (NFκB) is a family of dimeric transcription factors that 
mediates a wide range of cellular activities regarding its prominent capacity in gene 
expression control (Perkins, 2007). NFκB has been considered as a key determinant 
for inflammatory response owing to its profound role in inflammatory-related genes 
regulation (Li and Verma, 2002). In mammalian cells, NFκB complexes exist in 
different forms of heterodimers or homodimers of NFκB subunit members which 
include RelA (p65), RelB, c-Rel, p50, and p52. All NFκB family members share 
similar Rel homology domain at N-terminus for sequence specific DNA binding, 
nuclear localization, and dimerization. RelA (p65), RelB, and c-Rel contain non-
homologous transcriptional activation domain in their C-terminus to serve regulatory 
functions in the expression of target genes. The p50 and p52 subunits, without 
transcriptional activation domain, are synthesized from posttranslational cleavage of 
precursor p105 and p100 proteins which are encoded from nfκb1 and nfκb2 genes 
respectively. The p105 and p100 contain ankyrin repeated domain in their C-terminus 
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similar to IκBα proteins which allow these precursor proteins to inhibit NFκB 
activation (Perkins, 2007).  
NFκB activation and signaling pathways  
In an unstimulated state, NFκB dimers accumulate in the cytoplasm in 
association with inhibitory proteins which interfere with nuclear localization and DNA 
binding processes of NFκB (Hayden and Ghosh, 2004). The principle NFκB inhibitors 
include IκBα, IκBβ, and IκBε. These inhibitory proteins bind to NFκB at conserved 
nuclear localization sequences in the N-terminus. Alternative NFκB inactivation can 
be directed through p100 and p105 due to their homologous multiple ankyrin repeats 
resembling the IκB proteins structure (Perkins, 2007). Each inhibitor protein has 
preferential binding capacity to different NFκB dimers. For instance, IκBα is a major 
inhibitor for p65/p50 heterodimer, the most common NFκB complex in mammalian 
cells while IκBε predominantly binds to p65/p65 and c-Rel/p65 dimers. IκBβ 
preferentially engages to p65/p50 similar to IκBα (Boyce et al., 2010). NFκB 
complexes with IκBα and IκBε can shuttle between cytoplasm and nucleus but the 
nuclear export process is more active which causes predominant NFκB localization in 
cytoplasm. Additionally, IκBα also plays a role in deactivating NFκB by shuttling it 
back to cytoplasm (Huang et al., 2000; Lee and Hannink, 2002). Conversely, the 
inhibitor IκBβ retains NFκB in the cytoplasm due to its inability to promote 
cytoplasm-nucleus transport (Malek et al., 2001). 
The functions of NFκB are usually mediated through direct regulation of target 
gene expression in response to stimulation from different sources, especially 
inflammatory cytokines. Upon activated by various stimuli, such as TNFα, processing 
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of inhibitory proteins occurs through enzymatic events and leads to degradation or 
structural modification of the inhibitory proteins thus enables NFκB to relocate into 
nucleus where NFκB modulates the target gene expression (Perkins, 2007). Several 
NFκB activation pathways have been discovered and extensively studied. Major 
pathways consist of classical canonical and non-canonical pathways which 
predominantly depend on IκB kinase (IKK) function. Canonical pathway is mediated 
typically by p65/p50 in associated with IKK. Canonical pathway can be activated by 
TNFα, bacterial product lipopolysaccharide, IL1, and RANKL as an osteoclast 
regulator. Non-canonical pathway involves RelB/p52 which originally forms as a 
RelB/p100 inactive complex (Shih et al., 2011). Induction of noncanonical pathway is 
influenced by both IKK and NFκB-inducing kinase (NIK) following stimulation by 
certain stimuli such as RANKL, BAFF, LPS, CD40, and lymphotoxin receptors. 
Atypical NFκB activation pathway is regulated by different enzymes including 
tyrosine kinase and casein kinase-2 which act on IκBα phosphorylation following 
specific stimuli such as UV-light exposure for tyrosine kinase and hypoxia or 
hydrogen peroxide for casein kinase-2 (Boyce et al., 2010; Perkins, 2007). 
There are three core IKK subunits including IKKα, IKKβ, and IKKɣ (NEMO; 
NFκB essential modulator).  IKKα and IKKβ contain kinase domain in their N-
terminus. IKKɣ, lacking of kinase domain, contains multiple regulatory subunits 
which contribute to the initiation of canonical NFκB activation. In canonical pathway, 
stimulus-responsive activation of trimeric IKK complex of IKKα, IKKβ, and IKKɣ 
leads to phosphorylation, ubiquitination, and proteolysis induction of IκBα (Boyce et 
al., 2010). Genetic studies have indicated that IKKβ plays an important role in IκBα 
 15
phosphorylation in canonical pathway activation (Gerondakis et al., 1999). In 
noncanonical pathway, NIK is a key regulator of the activation process via direct 
phosphorylation and induction of IKKα-mediated phosphorylation of p100. 
Subsequently, the p52 formation from p100 is achieved through 26S-proteosomal 
relating process then RelB/p52 dimer translocates into nucleus for further functions 
(Shih et al., 2011). 
Transcriptional control functions of IKK/NFκB system are varied depending 
on the interaction of NFκB with other co-regulators which determines cell type- and 
stimulus-specific regulation of the target genes. After NFκB accumulates in the 
nucleus, NFκB interacts with co-activator or co-repressor which directs the modes of 
transcription control in either activation or suppression. Additionally, NFκB can bind 
with heterologous transcription factors which influence promoter targeting and 
selectivity (Perkins, 2007). 
NFκB involvement in physiological processes 
NFκB exerts a regulatory role in various physiological processes from 
inflammation, immunity, proliferation, differentiation to cell survival through 
intracellular signaling network with transcriptional and post-transcriptional regulation 
(Perkins, 2007; Sitcheran et al., 2003). Genetic approaches in animal studies have 
been used to identify the functions of each NFκB subunit and pathway in organ and 
tissue specific manners.  Table 1 summarizes transgenic and mutant mice models for 
investigating the function of major components in NFκB pathway in vivo (Gerondakis 
et al., 1999; Li and Verma, 2002). 
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Table1 Phenotype of mutant mice for NFκB related components 
Mutated gene Phenotype 
NFκB subunits  
p65 
p65 and c-rel 
Embryonic lethal at E15 – E16 from liver apoptosis 
Embryonic lethal at E13 - E13.5 from liver apoptosis 
p65 and nfκb1 Embryonic lethal at E13 - E13.5 from liver apoptosis 
relB Postnatal lethal due to organ inflammation from T-cell infiltration, 
defects in acquired and innate immunities,  
deficiency in dendritic cell development 
c-rel Impaired T and B cell responses 
nfκb1 (p105 and p50) Defect in B lymphocyte proliferation and activation 
nfκb2 (p100 and p52)  Disruption of spleen and lymph node architecture,  
impaired T cell response 
nfκb1 and nfκb2 Bone growth retardation, craniofacial abnormalities with 
osteopetrotic appearance, defects in osteoclasts and B cell 
development 
nfκb1 and RelB Postnatal lethal in 3-4 weeks due to organ inflammation,  
defect in B cell development 
nfκb1 and c-rel Defects in lymphocyte activation, diminished humoral immunity 
IκB proteins  
IκBα Postnatal lethal in 7-10 days from severe dermatitis and 
granulocytosis 
IκBα knockout and 
IκBβ knock-in 
Rescue phenotype of IκBα knockout mice 
IκBε Decreased CDD44-CD25+ T cells 
IKK complexes  
IKKα Neonatal lethal from morphological and skeletal defects due to 
impaired keratinocyte differentiation, defect in B cell development 
IKKβ Embryonic lethal at E12.5 – E14.5 from liver apoptosis 
IKKα and IKKβ Embryonic lethal at E11.5 – E12.5 from liver apoptosis 
IKKγ Embryonic lethal at E11.5 – E12.5 from liver apoptosis 
Related proteins  
NIK Disruption of spleen and lymph node architecture, lack of lymph 
nodes and Peyer’s patches 
  
Mice with genetic manipulation revealed unique and overlapping functions of 
individual Nfκb subunits and other components in NFκB pathway. All Nfκb subunits 
except p65 have profound effect on immune system. The function of p65 involves 
protective role in hepatocyte survival (Beg et al., 1995) which also presents in Ikkβ 
and Ikkγ null mice according to tight correlation of p65/p50 and Ikk complex in the 
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canonical pathway. Protective function of p65 is attributed to its potential in activation 
of anti-apoptotic genes A1/Bfl-1, Xiap, and Bcl-xL (Wang et al., 1996; Wang et al., 
1999). Embryonic lethality in p65 deficient mice impeded the studies of p65 functions 
in other organs in postnatal stage. Cells/tissues specific gene manipulation emerges 
growing knowledge of the significance of p65 in specific organs/tissues (Geisler et al., 
2007; Steinbrecher et al., 2008; Tang et al., 2010). Therefore decoding the role of p65 
in other organs can be accomplished to reveal new aspects of NFκB function. 
NFκB involvement in bone biology 
The fundamental participation of NFκB in bone biology has been addressed in 
both physiological and pathological conditions of osteoclasts and osteoblasts (Boyce 
et al., 2010; Novack, 2011). Aberrant NFκB activation, typically canonical pathway, is 
implicated in pathogenesis of several bone inflammatory diseases such as rheumatoid 
arthritis, inflammatory arthritis, osteoarthritis, and periodontitis (Nichols et al., 2001; 
Novack, 2011). NFκB is constitutively activated at lesion sites where inflammation is 
elevated. The pathogenic effect of NFκB is described by its potent transcriptional 
activation and responsive effect on inflammatory mediators from immune cells, 
osteoclasts, chondrocytes or osteoblasts. A list of involved mediators includes TNFα, 
IL1, IL6, IL8, cyclooxygenase 2 (COX2), matrix metalloproteinases (MMPs), and 
inducible nitric oxide synthase (iNOS) (Li and Verma, 2002; Novack, 2011). In 
addition to inflammatory related diseases, the pathogenesis of degenerative diseases 
osteoporosis and Paget’s disease of the bone also show the correlation with NFκB 
activation in osteoclasts.  
NFκB involvement during bone repair/regeneration is not well studied. A gene 
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profile study in osseointegration of implants in humans indicates a prominent 
IκB/NFκB cascade at early healing stage of day 4 postimplantation which correlates 
NFκB with initial inflammatory phase in bone healing process (Ivanovski et al., 2011). 
Owing to the profound effect of NFκB in inflammation, studies regarding 
inflammatory effects on bone fracture healing may infer the role of NFκB in bone 
repair/regeneration (Mountziaris et al., 2011).  Chronic inflammation causes damaging 
effect on bone regeneration whereas lack of inflammatory responses at initial stage of 
bone healing impairs regenerative potential of bone tissues which is the outcome of 
decreased osteoblasts function. It is imperative that NFκB may contribute to early 
stage of bone formation through osteoblasts regulation.  However, the function of 
NFκB in osteoblasts at early repair/regeneration stages remains unclear.   
The role of NFκB in osteoclastogenesis and bone resorption has been defined 
extensively. Mice with target deletion of nfκb1 and nfκb2 display defects in osteoclast 
development which impair bone resorption activities as shown by osteopetrotic 
phenotype and failure of tooth eruption (Franzoso et al., 1997). The osteoclast 
phenotypes in these nfκb1/nfκb2 knockout mice are similar to the findings in Rankl 
null mice which is a required factor for osteoclast development and activation (Xing et 
al., 2002). RANKL induces NFκB activation in canonical pathway through TRAF6 
and noncanonical pathways through NIK by activating IKKβ and IKKα (Chaisson et 
al., 2004; Liu et al., 2004). The study in p65-/-Tnfr-/- mice indicates that p65 subunit is 
involved in osteoclast development via apoptosis prevention but not osteoclast 
induction (Vaira et al., 2008).  
The    role    of    NFκB    in    bone    formation    from    the    perspective    of  
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osteoblastogenesis is less defined than for osteoclasts. Bone formation is a complex 
process that involves multiple pathways orchestrated in time- and stage-specific 
manners. In addition to the osteoclast defect, the nfκb1/nfκb2 knockout mice exhibit 
dwarfism phenotype with reduced Bmp2 mRNA level in growth plate of long bones 
(Feng et al., 2003). Bone growth retardation in this model was explained as 
consequence of compromised chondrogenesis through direct effect on Bmp2 induction 
which is attributed to p65-mediated transactivation.  BMP2 can induce both osteoblast 
and chondrocyte differentiation (Jang et al., 2011; Matsubara et al., 2008). Conflicting 
results from posttranscriptional function of NFκB illustrate that NFκB inhibits 
chondrogenesis and myogenesis by silencing Sox9 and MyoD, key determinants of 
chondrocyte and myoblast development respectively (Sitcheran et al., 2003). A recent 
study has identified the role of the canonical NFκB pathway in cells in osteoblastic 
lineage at mature stage by using transgenic mice that express a dominant negative Ikkγ 
(IKKγ-DN) driven by Bglap2, the osteocalcin promotor (Chang et al., 2009). Young 
mice with this Nfκb inhibition in differentiated osteoblasts showed increased 
trabecular bone mass as a result of increased osteoblast function. Additional function 
of NFκB in mature osteoblasts is implicated in osteoporosis pathogenesis as adult 
Bglap2-IKKγ-DN mice are resistance to ovarectomy-induced osteoporotic bone loss. 
Despite the function of NFκB in differentiated osteoblasts is defined, a mechanism 
during the early stages of bone formation may be critical to bone development. The 
importance of NFκB in osteoblast differentiation requires elucidation.  
NFκB may be significant  in  the  intrinsic modulation of  osteoblastic activity. 
The  underlying  mechanisms  in which  NFκB  controls  bone formation  are  partially 
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defined. The discoveries of pathways that NFκB directly regulates osteoblast as well 
as the regulatory mechanisms for NFκB function in osteogenesis will ultimately 
provide us fundamental knowledge in defining physiological process of bone 
development as well as developing novel bone regeneration approaches. The 
hypothesis of this dissertation is p65 mediated NFκB affects bone formation via 
osteoblast regulation. 
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CHAPTER 2 
 
HAPLOINSUFFICIENCY OF NFκB P65 MODULATES BONE 
DEVELOPMENT THROUGH OSTEOBLAST REGULATION 
 
Introduction 
Osteogenesis is a process of bone formation that is initiated by osteoblast 
function and regulated by coupled activities of osteoblasts and osteoclasts. The 
mechanisms for osteogenesis during bone development are separated into two distinct 
processes. In limb skeletons, osteogenesis takes place in endochondral ossification 
manner which begins with cartilage template before bone replacement by osteoblasts. 
Another mechanism is intramembranous ossification which forms bone directly from 
mesenchymal cell differentiation into osteoblasts as found in parts of craniofacial 
bones and clavicles. Both mechanisms terminally engage in calcified extracellular 
matrix synthesis by osteoblasts (Katagiri and Takahashi, 2002; Rodda and McMahon, 
2006).  
Successful bone formation requires sufficient number of functional osteoblasts 
to establish extracellular structural components of bone tissues. During osteogenesis, 
mesenchymal stem cells differentiate into osteoprogenitor cells before developing into 
proliferating pre-osteoblasts  which  turn  into  mature  osteoblasts  that  perform  bone   
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production (Baek et al., 2010; Nakashima et al., 2002). Coordination of a multitude of 
different extrinsic factors from paracrine, autocrine, and endocrine origins influences 
intrinsic regulation of osteoblast development and maturation (Aubin, 2001). Only a 
few molecules have been exemplified their mechanistic potential to promote bone 
formation through direct effect on osteoblasts such as PTH, BMPs, Wnt (Cao and 
Chen, 2005; Guo and Cooper, 2007; Weber et al., 2006). The underlying mechanisms 
which regulate osteoblast development and function remain partially defined.  
Inflammation is a fundamental process that impacts bone homeostasis in 
physiological and pathological conditions of bone. Various cellular activities 
corresponding to inflammatory reaction are directed by a transcription factor NFκB 
(Perkins, 2007). Although the effect of NFκB on osteoclastogenesis is well defined, 
little is known about direct roles of NFκB in osteoblast differentiation. Previous 
studies have suggested the roles of NFκB in skeletal growth and development through 
osteogenesis. Suppression of p65 activation by pharmacological NFκB inhibitor, 
PDTC and BAY, results in reduced in vitro growth of metatarsal growth plate (Wu et 
al., 2007). The negative influence of p65 NFκB subunit in lineage selection during 
mesenchymal differentiation towards other lineages suggests a favorable effect on 
lineage specification of osteogenic pathway. The p65 dependent NFκB activity 
suppresses myogenesis and chondrogenesis through post-transcriptional gene silencing 
of MyoD and Sox9 genes (Sitcheran et al., 2003). NFκB and p65 subunit alone have 
been shown to inhibit adipogenesis by blocking DNA binding potential of the key 
adipogenic transcription factor PPARɣ (Suzawa et al., 2003). Moreover, the influence 
of p65 on Bmp2 expression, a potent osteogenic growth factor, has been demonstrated 
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at transcriptional regulation level with direct binding of p65 on the Bmp2 promoter 
region (Feng et al., 2003). Mice lacking p50 and p52, the major p65 dimeric pairs, 
exhibit bone growth retardation with reduced amount of Bmp2 in growth plate of long 
bones ( Feng et al., 2003; Franzoso et al., 1997). Collective evidence from these 
findings suggest that p65 mediated NFκB activity may be critical for osteogenesis 
during bone development. However, embryonic lethality of p65 null mice due to liver 
apoptosis and the superimposed function of NFκB in osteoclasts precluded the work 
on defining in vivo function of p65 mediated NFκB in osteogenic cells (Beg et al., 
1995; Vaira et al., 2008). 
To explore the specific role of p65 mediated NFκB on osteogenesis during 
bone development, we exploited conditional gene targeting approach to abrogate p65 
function in osteogenic cells in vivo using Cre/loxP recombination strategy. Mice 
lacking one p65 allele in osteogenic cells displayed smaller skeleton. Decreased 
mineralization from impaired osteoblast differentiation and elevated apoptosis affected 
the qualitative and quantitative properties of bones in these mice. These findings 
provide in vivo evidence that p65 mediated NFκB is required for maintaining 
osteogenic cells in normal physiological condition of bone homeostasis.  
 
Materials & methods 
Animals 
Generation of mice with p65 haploinsufficiency 
Mice with targeted deletion of p65 gene in osteoprogenitors were generated 
using a Cre-LoxP system. Mice in which exons 5-8 of p65 (exons encoding most of 
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Rel homology domain) were flanked with loxP sites (p65fl/fl) were obtained from Dr. 
Albert S Baldwin, University of North Carolina at Chapel Hill (Steinbrecher et al., 
2008). Transgenic mice that expressed GFP linked Cre-recombinase under the control 
of the Osx promoter (Osx-Cre) (Rodda and McMahon, 2006) were purchased from the 
Jackson Laboratory. The p65fl/fl mice were crossed with Osx-Cre mice to create mice 
in which one allele of p65 gene was deleted in osteoprogenitor cells (p65fl/+Osx-Cre). 
Animals were housed under specific pathogen-free conditions with filtered air and fed 
with autoclaved diet and water. All experiments were performed in accordance with 
the protocols approved by the Institutional Animal Care and Use Committees of the 
University of North Carolina. The genotypes of studied mice were identifined by PCR 
amplification of genomic DNA isolated from tail biopsies or ear clip with proteinase K 
digestion protocol. The Cre transgene was analyzed using two primer sets according to 
the Jackson Laboratory protocol for Cre PCR reaction: CreF (GCG GTC TGG CAG 
TAA AAA CTA TC), CreR (GTG AAA CAG CAT TGC TGT CAC TT), internal 
control F (CTA GGC CAC AGA ATT GAA AGA TCT), internal control R (GTA 
GGT GGA AAT TCT AGC ATC ATC C). The wild-type p65 and p65loxP allele were 
identified using the following primer pair: p65loxP F (CGA CTT TGG GTT GGA 
GGG TTA CAG AAG GC) and p65loxP R (TGG TCT GGA TTC GCT GGC TAA 
TGG C). The wild-type and p65loxP alleles were represented by 450-bp and 510-bp 
PCR products respectively. The presence of both bands represents a heterozygous 
genotype for p65loxP allele. The recombination of p65 allele which verified target 
deletion of the p65loxP allele was detected by a PCR approach using primers: 
recombination F (TCT TCT CAA CTC CAG GGG AAT AGG), recombination R 
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(CAC CAT TGT TTT CTC ACT TGG CAC). The 1113-bp product band represented 
successful p65loxP recombination (Steinbrecher et al., 2008).  
Whole mount skeletal staining  
Skeletal structures of newborn mice at day1 and day2 were determined by 
alizarin red S and alcian blue staining as described previously (McLeod, 1980). 
Briefly, animals were deskinned, eviscerated, and fixed in ethanol for at least 5 days 
and then in acetone for 2 days. The skeleton was stained with alizarin red S and alcian 
blue solution for 3 days at 37oC before being cleared in 1% KOH and taken through 
gradient steps to 100% glycerol. 
Microcomputed tomography (µCT) 
Images of mineralized skeletal structures from newborn (P2), young (P8), and 
adult mice (11 weeks) were acquired using a desktop microtomographic imaging 
system (Skyscan 1074HR, Aartselaar, Belgium) at a resolution of 20.5 µm/pixel. 
Standardized scanning and image reconstruction settings were used. Humeri of P2 
animals were assessed for skeletal dimension and morphology with the following 
parameters: length, diameter, circumference, and cortical thickness at mid-diaphysis 
region. Trabecular regions of proximal tibiae and cortical regions of mid-diaphysis of 
tibiae from P8 mice were used for the analysis of bone length, bone mineral densities, 
and bone morphology. For trabecular bone, the measured parameters were bone 
mineral density (BMD), bone volume fraction (BV/TV), bone specific surface 
(BS/BV), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), and trabecular 
number (Tb.N). For cortical bone, the determined parameters included cortical BMD, 
total cross sectional bone area (B.Ar), mean total cross sectional bone perimeter 
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(B.Pm), and mean polar moment of inertia (MMI). Craniofacial skeletons of week 11 
gender-matched mice were assessed and analyzed for premaxillary deviation. 
Hydroxyapatite phantoms (250 mg/cc and 750 mg/cc; CIRS, Inc., Norfold, VA) were 
use as references for BMD calculation. 
Cellular and histological characterization 
Histological evaluation 
The specimens were fixed in 4% phosphate-buffered paraformaldehyde, 
decalcified with buffered 0.2 mM EDTA (pH 7.4), embedded in paraffin, and serial 
sectioned at 5-µm thickness. Sections were stained with hematoxylin-eosin for 
morphological examination or stained for other analyses. (Nikon Eclipse50i, Nikon, 
Melville, NY) 
Primary cells isolation and cell culture 
Osteoprogenitor cells were isolated from calvariae of 8-day old mice by serial 
digestion in Dulbecco’s modified Eagle’s medium (DMEM, Gibco Invitrogen) 
containing 0.25% trypsin a, 0.1% EDTA, and 0.8 mg/ml type II collagenase (Sigma, 
St. Louis, MO). Calvariae were digested for 30 min at 37°C with constant agitation. 
The digestion solution was collected, washed with fresh medium, and digested five 
additional times. Cell suspensions from the digestion were centrifuged for 5 min at 
300x g then resuspended and cultured in DMEM supplemented with 10% fetal bovine 
serum (FBS), 100 units/ml penicillin/streptomycin (regular medium) for 24 hours. 
Medium was changed every three days. To induce osteoblastic differentiation, cells 
were cultured in regular medium supplemented with 50 µg/ml L-ascorbic acid, 10 mM  
β-glycerophosphate, and 10-7M dexamethasone (osteogenic supplement).  
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Bone marrow cells were flushed from femurs and tibiae of 9-week old mice 
with α-MEM. Erythrocytes were lysed with 0.8% ammonium chloride. Bone marrow 
cells were cultured in triplicate in MesenCult™ MSC media with mesenchymal stem 
cell stimulatory supplements (Stem Cell Technologies, Vancouver, BC, Canada) with 
100 U/ml of penicillin and 100 µg/ml of streptomycin in 6-well plates. Cells were 
allowed to adhere to the plastic support for 24 hours before the first medium change 
into the conditions with or without osteogenic supplement. The murine mesenchymal 
precursor cell line C2C12 was obtained from ATCC (Manassas, VA) and maintained 
in DMEM supplemented with 10% FBS, 100 units/ml penicillin/streptomycin.  
Immunoblotting analysis 
Total calvarial cell lysates (10 µg protein/lane) and protein extracted from 
flushed tibia/femoral bones of adult mice (20 µg protein/lane) were fractionated in 
10% SDS-PAGE and transferred to PVDF membranes. The membranes were 
incubated with primary antibodies, anti-beta actin, and horseradish peroxidase 
conjugated goat anti-rabbit antibody (Amersham Biosciences, Pittsburgh, PA). The 
primary antibodies were rabbit polyclonal antibodies against p65, RelB, c-Rel, 
p100/p52 (Cell signaling Technology number 4764, 4954, 4174, 4882) and p105/p50 
(Santa Cruz Biotechnology number SC7178). The immunocomplexes were detected 
by chemiluminescence using ECLPlus (Amersham Biosciences). The densities of the 
bands representing target proteins and beta-actin proteins were quantified using UN-
SCANT-IT gel software (Silk Scientific, Orem, UT). 
Quantitative real-time PCR  
Isolated calvarial cells were seeded in 48-well plates at a density of 1.2 x 104 
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cells/well. To determine the RNA expression of osteogenic differentiation markers, 
cell layers were maintained in regular media or osteogenic media for 7 days. Total 
RNA was extracted from calvarial cells by TriZol reagent (Invitrogen, Carlsbad, CA). 
First-strand cDNA was synthesized using SuperScriptIII first-strand synthesis 
supermix for qRT-PCR kit (Invitrogen). Relative quantification of mRNA abundance 
was performed by real time RT-PCR procedure using ABI prism 7500 system. 
Selective markers included Runx2, Osx, Alp, Bsp, and Bmp2 (ABI assay No. 
Mm00501578_ml, Mm00504574_ml, Mm00475831_ml, Mm00492555_ml, 
Mm01340178_ml respectively). All reactions were amplified using Taqman Universal 
PCR Master Mix (Applied Biosystems, Foster City, CA).  Assays were performed in 
duplicate and the results were normalized to rodent GAPDH expression (ABI assay 
No. 4308313). The fold changes were calculated using the values obtained from the 
p65fl/+ in regular media group as a calibrator then determined by means of 2-∆∆Ct 
method (Livak and Schmittgen, 2001).  
Alkaline phosphatase activity  
Alkaline phosphatase activity was measured in total lysates from calvarial cell 
layers after incubating in regular medium or medium with osteogenic supplement for 2 
days. Cells were washed with PBS and harvested with 0.1% triton-X100 in PBS 
before evaluation for Alp activity using p-nitrophenyl phosphate substrate (Sigma, 
St.Louis, MO, USA; Asahina et al., 1996). Protein concentration was assessed by 
BCA protein assay (Pierce). The enzymatic activity was calculated as 
µM/minute/protein concentration from standard p-nitrophenol curve then normalized 
with protein concentration.  
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CFU-F/CFU-OB assays and TRAP staining 
After culturing in differential/growth medium for 14 days, cell layers explanted 
from mouse bone marrow were washed with PBS and then fixed in 100% cold 
methanol for 10 minutes. The cultured fibroblastic colonies were stained with 2.5% 
crystal violet staining in 70% methanol for 5 minutes at room temperature then rinsed 
with water. Formation of CFU-OB was detected by alkaline phosphatase activity 
staining (Sigma, St. Louis, MO, USA) after incubation at 370C for 30 minutes, and 
washing with PBS for 5 times. The colonies (>50 cells/colony) were counted under 
inverted microscope. GFP representing Cre recombinase enzyme expression was 
monitored in the cells cultured for CFU-OB assay using a fluorescent microscope 
(Olympus-IX51, Olympus, Central Valley, PA).  
Osteoclastogenic potential was confirmed with in vitro TRAP staining as 
described previously (Yan et al., 2007). Briefly, bone marrow cells (1 x 105 cells/well) 
were seeded onto 48-well plates. The cells were maintained in αMEM containing 10% 
FBS, 100 U/ml penicillin/streptomycin supplemented with 20 ng/ml recombinant mM-
CSF (R&D Minneapolis, MN) and 60 ng/ml recombinant  human soluble RANKL 
(PeproTech Inc, Rocky Hill, NJ) for 6 days. The supplemented medium was changed 
every 3 days. After fixation in 10% formalin, cells were stained with 0.1 mg/ml of 
naphthol AS-MS phosphate and 0.6 mg/ml fast red violet LB salt in 0.1 M sodium 
acetate buffer containing 50 mM sodium tartrate. The numbers of TRAP positive cells 
with three or more nuclei were counted at 100X magnification. The number of 
osteoclasts in vivo was quantified by TRAP positive staining of the cells in 
tibia/femoral bone sections of 8-week old mice. The pictures were taken using a light 
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microscope (Nikon Eclipse50i) with a digital camera (Nikon digital camera 
DXM1200F, Nikon, Melville, NY). The numbers of TRAP positive cells were 
counted using the ImageJ software (Yan et al., 2007).  
Cell proliferation and apoptosis analyses  
For cell proliferation, calvarial cells at density 1 x 104 cells per well were 
plated in triplicate onto a 96-well plate and cultured in regular medium for up to 7 
days. Cell proliferation rate was assessed by MTS assay (Promega, Madison, WI) at 
day 1, 3, 5, and 7, according to the manufacturer’s protocol. The absorbance values 
representing the amounts of formazan compound produced by metabolically active 
cells were measured using a Model 550 microplate reader (Biorad) at 490 nm 
wavelength.  
To evaluate the roles of NFκB in osteogenesis regarding osteoblast survival 
protection, calvarial cells derived from studied mice (1 x 104 cells/well of 96-well 
plate) were assessed using cell viability and caspase3/7 fluorimetric assays (Promega) 
in the presence and absence of 1 nM staurosporine. The absorbance reflecting viable 
cell numbers and caspase3/7 activity was determined with a fluorescent microplate 
reader (Spectramax M2, Molecular Devices, CA). In situ apoptosis of bone cells was 
detected by TUNEL staining (Trevigen, Gaithersburg, MD) on sections from tibiae of 
day8 studied mice. At least two sections from each bone were performed for terminal 
deoxynucleotidyl transferase-mediated deoxyuridine triphosphate (Tdt) nick end 
labeling according to the manufacturer’s protocol. A positive control was performed 
by incubating the tissue section with nuclease solution prior to the labeling procedure. 
A negative control without Tdt was also included in the experiment. TUNEL positive  
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cell numbers were determined by direct cell counting in subchondral area.  
Luciferase reporter assay and plasmids/virus 
The Ad.NFκBLuc adenovirus was kindly provided by Dr. John F Engelhardt 
(University of Iowa). The p65-CMV and IκB-SR-CMV expression vectors were 
obtained from Dr. Albert S Baldwin (University of North Carolina at Chapel Hill). 
The mBmp2-luc plasmids were kind gifts from Dr. Di Chen (University of Missouri).  
For NFκB transactivational activity assessment, calvarial cells derived from 
the studied mice were transduced with Ad.NFκBLuc adenovirus (MOI=20) for 2 hours 
in serum free medium then 20% FBS supplemented medium was added and 
maintained to total of 24-hour transduction period (Sanlioglu et al., 2001). The 
medium was replaced with regular growth media containing 100 ng/ml of TNFα or 
PBS control for 4 hours prior to luminescence evaluation. Luciferase signal 
quantification was performed using luciferase assay (Promega) in a Lumat LB 9507 
(Berthold Technologies, BadWildbad, Germany). Luciferase activity was normalized 
to the protein concentration and reported as fold induction. 
For evaluation of NFκB capacity on Bmp2 induction, C2C12 cells were seeded 
onto 48-well plates one day before transfection. A variety of mouse Bmp2-luc 
constructs were co-transfected with p65-CMV vector in the presence or absence of 
IκB-SR-CMV vector. The plasmid cDNA3.1 (Invitrogen) was used as an empty vector 
to equalize the amount of plasmid transferred into each reaction. All transfections 
included a constitutively expressed Renilla luciferase plasmid (pRL-TK), using 
SureFECT reagent (SABiosciences, Frederick, MD). Twenty four hours after 
transfection, cells were harvested and luciferase activities were measured using Dual 
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Luciferase assay (Promega). The luciferase signal was normalized to Renilla luciferase 
activity.  
Statistical analysis 
All experiments were performed in duplicate or triplicate. The data were 
calculated and presented as mean + S.D. Statistical analyses were performed using 
Student’s t-test or analysis of variance or non-parametric test. Significant difference 
was considered when p<0.05.    
Results 
Generation of mice with p65 haploinsufficiency in osteogenic cells and 
characterization of the gross phenotype 
Defining the physiological role of p65 in osteoblasts in animal models has 
been difficult due to the embryonic lethality in mice lacking p65 subunit and its 
redundant effect on osteoclast differentiation and function. To clarify the function of 
p65 NFκB in osteogenesis, mice with p65 haploinsufficiency in osteoprogenitors 
(p65fl/+Osx-Cre) were examined. Transgenic mice expressing Cre recombinase under 
the control of Osx promoter (Osx-Cre) were bred with loxP-flanked p65 mice (p65 fl/fl) 
to generate mice with p65 haploinsufficiency in osteoprogenitor cells (p65fl/+Osx-Cre). 
The p65fl/+ littermates were used as controls since they are indistinguishable from wild 
type C57BL/J mice (Steinbrecher et al., 2008). The specificity of Osx-Cre function, 
determined by p65 recombination gene product, was present in bone but not in heart, 
kidney, spleen, and liver (Fig.1C). Targeted disruption of one p65 allele was verified 
by diminished p65 protein levels. A 20-40% reduction in whole cell extracted p65 
levels was seen in isolated calvarial cells from 8-day-old mutant mice compared to 
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controls. Lower p65 protein (p65/β-actin ratio of p65fl/+ versus p65fl/+Osx-Cre 2.62 + 
0.76 and 1.25 + 0.66) was also observed from total protein isolated from long bones of 
adult mutant mice (Fig.1D).  Immunoblot data of other NFκB subunits illustrated 
comparable levels between p65fl/+ control and p65fl/+Osx-Cre mice, indicating that the 
reduced amount of p65 from haploinsufficiency does not cause compensatory 
response of other NFκB subunits at physiological condition.  
The p65fl/+Osx-Cre progeny were born in an expected genetic ratio. Mice were 
viable and fertile. To determine whether NFκB affected osteogenesis, whole mounted 
stained skeletons of the mutant newborns were compared with the control skeletons. 
Morphologically, p65fl/+Osx-Cre mice exhibited noticeably reduced sizes with 
proportionally smaller skeletons since birth (Fig.1A). Their body sizes remained 
smaller at 8 days and 11 weeks old. Their mean body weights were significantly lower 
in comparison with the controls for both genders (Fig.1E). When comparing between 
genders, the weight differences between mutants and controls were larger in male 
mice (Male 25-47% vs Female 18-37% at 8 to 3 weeks of age respectively, p<0.001). 
As Osx-Cre is present in both endochondral and intramembranous bony 
elements (Rodda and McMahon, 2006), detectable bone phenotypes were represented 
in craniofacial and long bones of p65fl/+Osx-Cre mice (Fig.2). Skeletal staining 
revealed less bone mineralization, and reduced skeletal dimension particularly in 
craniofacial bones in p65fl/+Osx-Cre neonates. Reduced skeleton sizes along with 
impaired bone deposition in frontal, parietal, nasal bones were observed in postnatal 
day2 (P2) stages (Fig.2A). The craniofacial phenotypes in p65fl/+Osx-Cre mice 
remained until adulthood with smaller skulls and premaxillary deviation (Fig.2B). 
 42
Mean degrees of deviation measured by angle between premaxillary suture and frontal 
suture were 3.79+1.53 in p65fl/+Osx-Cre and 0.63+0.69 in p65fl/+ controls (Fig.2C; 
p<0.001). In endochondral bones, overall reduction of skeletal dimensions with 
metaphyseal flaring was observed in scapula, humeri, tibiae, and femurs of P2 
mutants. Growth plates of these bones were also proportionally longer when compared 
with those from P2 controls (Fig.2D).    
MicroCT analysis confirmed quantitative reduction in bone dimension and 
architecture in p65fl/+Osx-Cre mice. Dimension and cortical thickness of humeri from 
P2 mutant mice were significantly smaller than those from controls (Table 2, p<0.05). 
Similar phenotypes were detected in later stage (P8) as observed in femur length 
(p65fl/+ 4.010+0.23 mm, p65fl/+Osx-Cre 3.647+0.26 mm., p<0.05), tibia length and 
perimeter (Fig.3, p<0.05). Cortical tibia bone morphology of P8 mutant mice was 
significantly different from the controls. Cortical bone area and mean polar moment of 
inertia were lower in p65fl/+Osx-Cre mice (p<0.05). Tibia trabecular bone of the 
mutant mice also indicated altered architecture in compared with the controls. Lower 
trabecular number was observed in proximal regions of p65fl/+Osx-Cre tibiae (p<0.05) 
with less trabecular thickness and trabecular separation. However, bone mineral 
densities from cortical and proximal trabecular tibia bone were not significantly 
different between mutants and controls.  
The p65fl/+ femurs from P8 mice showed typical cortical and trabecular 
compartments with normal cellular organization. In the mutant p65fl/+Osx-Cre mice, 
thinner cortical and less dense trabeculae appeared in the ossification zone (Fig.2E). 
Cell density at the chondroosseous junction was lower in the mutant mice, implying to 
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the reduced number of osteogenic cells. Taken together, deletion of one p65 allele in 
osteogenic cells affected skeletal dimension and architecture from early postnatal 
stage to adulthood. 
Targeted disruption of p65 single allele impaired osteoblast differentiation 
To address the direct effect of NFκB disruption in osteogenic cells, calvarial-
derived osteoprogenitors from young (P8) p65fl/+Osx-Cre and p65fl/+ littermates were 
isolated and characterized. Reduced skeletal dimension of p65fl/+Osx-Cre could be a 
consequence of either reduced numbers of bone forming cells or decreased 
differentiation potential of these cells. The proliferation rate of the isolated calvarial 
cells, determined with MTS assay, showed no significant difference between cells 
with one p65 allele and controls (Fig.4). Cellular assays comparing p65fl/+Osx-Cre 
with the controls demonstrated reduced differentiation markers in both mRNA and 
early osteoblastic activity. Cultured p65fl/+Osx-Cre calvarial cells had markedly 
reduced expression levels of osteoblast-specific mRNAs including Runx2, Osx, Alp, 
and Bsp (Fig.5D). Alp activity, an early osteoblast differentiation marker, significantly 
decreased in calvarial cells from p65fl/+Osx-Cre mice (Fig.5C, p<0.05).  
Reduced osteogenic potential in p65fl/+Osx-Cre mice was verified by 
comparison of bone-forming capacity of MSCs from these mutants versus 
p65fl/+controls. Formation of CFU-F/CFU-OB was examined in freshly isolated bone 
marrow stromal cells from 9-week old mutant and control mice. Consistent with 
calvarial data, CFU-F from p65fl/+Osx-Cre and control mice were comparable (Fig.5A; 
p=0.276) while CFU-OB from p65fl/+Osx-Cre MSCs were fewer for than controls 
(p<0.05). The CFU-OB/CFU-F ratio from the mutants was 34% and 54% from the 
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controls, implicating that deletion of one p65 allele affected dynamic of the MSCs 
population. The GFP emission in CFU-OB of p65fl/+Osx-Cre was observed after 12 
days in culture which indicated the expression of cre-recombinase enzyme during 
osteoblastic differentiation (Fig.5B). Additionally, osteoclastogenic potential of 
p65fl/+Osx-Cre and control bone marrow stromal cells were assessed following mCSF 
and sRANKL induction. The numbers of TRAP staining positive cells from both 
groups were not different (p65fl/+ versus p65fl/+Osx-Cre 376+51 VS 365+43; p>0.05) 
and no significant difference was seen in osteoclast numbers from in vivo TRAP 
staining (p65fl/+ versus p65fl/+Osx-Cre; Chondro-osseous junction 31+16.9 VS 21+1.4; 
Trabecular region 60+15.5 VS 71.5+16.3 cells; p>0.05), indicating that there was no 
confounding effect from osteoclast formation in this model (Fig.6).   
Effect of p65 disruption on osteogenic cell survival  
To determine the role of NFκB/p65 in osteoblast survival, in vitro and in vivo 
apoptosis/survival tests were exploited. Caspase3/7 activity from cultured p65fl/+Osx-
Cre calvarial cells was higher than controls in both normal and staurosporine induced 
apoptosis conditions (Fig.7A; p<0.05). Cell survival from p65fl/+Osx-Cre, as analyzed 
by fluorometric cell viability measurement, was lower than controls in both 
conditions.  In situ apoptosis evaluation showed consistent results with the in vitro 
findings. More TUNEL positive cells were observed in subchondral area of tibia bones 
of 8-day-old p65fl/+Osx-Cre mice (Fig.7B, 70.5+12.21 VS 20+7.45; p=0.001). 
Collectively, the elevated apoptosis in osteogenic cells with lack of one p65 allele 
suggested a protective role of p65 in osteogenic cell survival which may partially 
explain how NFκB influences osteogenesis. 
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Roles of p65 in osteoblast differentiation through transactivation of Bmp2 
genes 
The impact of p65 NFκB on BMP2 expression was suggested during osteoblast 
differentiation in human mesenchymal stem cells (Hess et al., 2009). Two NFκB 
responsive elements function in the promoter region of Bmp2 gene (Feng et al., 2003). 
To examine the diminution of p65/NFκB modulating osteogenesis, NFκB 
transactivation activities in primary calvarial cells were quantified by luciferase assay 
following transduction of luciferase adenovirus containing NFκB responsive element. 
Less luciferase reporter signal in p65fl/+Osx-Cre calvarial cells demonstrated reduction 
of NFκB transcriptional activity upon 4 hours of TNFα stimulation (Fig.8A, p<0.001). 
To confirm the potential NFκB transactivation effect on Bmp2 induction, a simple 
transfection approach in which modulation of p65 NFκB by p65 and IκB-SR (a 
constitutively negative NFκB signaling regulator) plasmids were conducted in a 
mouse stem-like cell line, C2C12 cells. Overexpression of p65 resulted in elevated 
induction of Bmp2 promoter-driven luciferase expression. Conversely, coexpression of 
p65 and IκB-SR showed significantly blunted luciferase production to basal level 
(Fig.8B). These observations were corroborated with decreased Bmp2 mRNA levels in 
primary p65 haploinsufficient calvarial cells in compared with the controls (Fig.8C). 
These results suggested that reduced osteogenesis from NFκB signaling reduction may 
be partly the consequence of decreased Bmp2 expression. 
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Figure 1 Characteristic of p65fl/+ versus p65fl/+Osx-Cre phenotype. Reduced 
amounts of p65 protein in osteogenic cells resulted in smaller body sizes in heterozygotes 
carrying one functional p65 allele. A) Whole mount skeletal preparations of p65fl/+ (wild type 
control) and p65fl/+Osx-Cre newborns at postnatal day2. B) PCR genotyping of p65 flanked 
loxP and Cre allele genes: p65fl/fl, homozygous p65 loxP; p65fl/+, heterozygous p65 loxP; WT, 
wild type. C) PCR genotyping of p65 recombination demonstrated tissue specific mutation of 
p65 gene in bone from p65fl/flOsx-Cre and p65fl/+Osx-Cre mice. D) Immunoblotting of NFκB 
protein levels from total lysates of isolated calvarial cells and from tibia/femoral bones 
obtained from p65fl/flOsx-Cre and p65fl/+Osx-Cre mice. n=3 animals/group. Experiments were 
done independently in triplicate. E) Mean body weight of p65fl/+ and p65fl/flOsx-Cre mice from 
age of 3 weeks to 8 weeks old. n=10/group *, p<0.001 versus p65fl/+ male mice; #, p<0. 001 
versus p65fl/+ female mice. 
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Figure 2 Gross phenotype. Conditional removal of p65 allele in osteogenic cells affects 
skeletal development. A) Alizarin red/alcian blue staining of skulls of P2 p65fl/+ control and 
p65fl/+Osx-Cre mutant pups. Dorsal and ventral views of skulls of P2 control and mutant mice 
showed less mineralization in premaxilla, nasal and parietal bones. n=10/group B) Gross 
structure of skulls from week-11 male mutant mice in compared with controls C) Comparison 
of angle between premaxillary suture and frontal suture from gender matched week-11 p65fl/+ 
and p65fl/+Osx-Cre mice. Data are shown as mean+SD.  n= 10-11 animals/group. *, p <0.05 
versus p65fl/+ samples. D) Higher magnification of forelimbs, hindlimbs, and tibia. Black 
arrowheads indicate metaphyseal flaring in the long bones of p65fl/+Osx-Cre pups. E) The 
proximal growth plate of femurs from P8 p65fl/+ and p65fl/+Osx-Cre mice stained with 
hematoxylin and eosin. n=3/group  
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2.006+0.068 1.754+0.068* Circumference  
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Table 2 µCT measurements of humerus bones in gender-match day2 p65fl/+ and 
p65fl/+Osx-Cre pups 
*p<0.05 versus p65fl/+ controls, n = 6-7 animals per group.  
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Figure 3 µCT analysis of femur bones from day 8 mice. Comparison of trabecular and 
cortical bone morphology and BMD in the region of proximal tibia bone from gender-matched 
p65fl/+ control and p65fl/+Osx-Cre mice. Data are shown as mean + SD. n=8 animals/group. *, p 
<0.05 versus p65fl/+ samples.  
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Figure 4 Cell proliferation. Proliferation pattern of calvarial cells derived from 8-day old 
p65fl+ and p65fl/+Osx-Cre mice. Absorbance at 490 nm was measured to detect formazan 
produced by live cells at indicated time points. Data are presented as mean + SD. 
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Figure 5 Osteoblast differentiation analyses. In vitro differentiaion assays provide 
evidence of reduced osteoinductive potential in p65fl/+Osx-Cre mice. A) CFU-Fs and CFU-
OBs in the bone marrow from femur/tibia bones of 9-week old mice of the indicated 
genotypes. Mean CFU-F colonies/1.5x106 BMCs. Mean CFU-OB colonies/2.5x106 BMCs. n= 
8-10 animals per group/condition B) CFU-OBs staining obtained from p65fl/+ Osx-Cre mutants 
and controls. Colonies from CFU-OBs of p65fl/+ Osx-Cre samples expressed GFP attributed to 
the presence of Osx-Cre recombinase after 12-day incubation in osteogenic media. C) 
Alkaline phosphatase activity of calvarial cells from 8-day old wild type and mutant mice after 
2 days culture was assessed by p-nitrophenol assay. D) Relative expression levels of early 
osteoblastic gene markers after 10-day osteogenic media induced differentiation on calvarial 
cells from studied mice. Differentiation was assessed by realtime PCR for Runx2, Osx, Alp, 
Bsp. n=5 animals per group/condition. Data are shown as mean + SD. *, p<0.005 versus p65fl/+ 
control.  
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Figure 6 Osteoclastogenic potential analyses. Haploinsufficiency of p65 in osteoblasts 
does not alter osteoclasts population. A) TRAP staining of osteoclasts derived from bone 
marrow cells isolated from p65fl/+Osx-Cre mutant and B) control mice. C) Mean TRAP 
positive cells/1.0x106 BMCs. n= 2 animals per group in quadricate. Data are shown as mean + 
SD.  p>0.05 versus p65fl/+ control. D) TRAP staining of sections from femurs of 8-week old 
p65fl/+Osx-Cre and E) p65fl/+ mice. n=3 animals/group.  
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Figure 7 Apoptosis analyses. Lack of a functional p65 allele results in increased apoptosis 
in osteoblasts. A) Caspase-3/7 activity and cell viability (Fluorescent RFU) in calvaria cells 
isolated from wild type p65fl/+ control and mutant mice. Cells were challenge with 1 µM 
Staurosporine-induced apoptosis or normal saline for 24 hours prior to measurement with 
fluorometric analysis. B) In situ apoptosis was determined in tibia bones by counting TUNEL 
positive cells in the metaphysis areas which showed higher apoptotic cells in 8-day old p65fl/+ 
Osx-Cre mice. n=3 animals/group. Data are shown as mean + SD. * p<0.05, # p<0.005 versus 
p65fl/+ control. Scale bar represent 10 µM. 
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Figure 8 Effect of p65 on the induction of Bmp2 promoter activities. A) 
Transactivational activity of NFκB in calvarial cells from studied animals, assessed with 
luciferase reporter assay following 24-hour transduction of Ad.NFκBLuc then 4-hour 
challenge of 100 ng/ml TNFα or PBS. B) Luciferase reporter assays were performed in C2C12 
cells using co-transfection of osteoblastic-related responsive luciferase reporters and p65 
plasmid with or without stabilized mutant IκBα (IκB-SR) plasmid. The target constructs 
included Bmp2 promoters with different deletions of promoter sizes (-150/+165, -2457/+165, 
and -2712/+165). Cells were transiently transfected for 16 hours and incubated in normal 
growth medium for 24 hours prior to measurement. The luciferase activity was calculated as 
relative fold change by normalization with Renilla luciferase activity. C) Relative Bmp2 gene 
expression from calvarial cells from day-8 old wild type and mutant p65fl/+ Osx-Cre mice. n=5 
animals per group/condition. *, p<0.005 versus p65fl/+ control. 
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Discussion 
NFκB plays pivotal roles in controlling a wide range of genes influencing 
diverse cellular activities including cell proliferation, differentiation, and apoptosis 
(Shih et al., 2011). Modulating NFκB activity is one therapeutic target in 
inflammatory bone diseases based upon the role of NFκB in osteoclast regulation 
(Jimi et al., 2004; Makarov, 2001; Nichols et al., 2001). P65 is a major functional 
subunit of NFκB family. The structure of p65 consists of 2 major domains, amino-
terminal Rel homology domain serving for DNA-binding and dimerization and 
carboxyl-terminal transactivation domain serving for transcription regulation (Perkins, 
2007). Activation of p65 NFκB is mediated primarily by phosphorylation of IκB in 
IKK dependent pathway.  The trimeric IKK complex typically consists of three 
subunits including two key catalytic subunits, IKKα and IKKβ, which interact with 
IKKɣ regulatory subunit (Chen and Greene, 2004; Perkins, 2007; Shih et al., 2011). 
IKK complex inhibits most, but not all, activities of p65 NFκB as illustrated by 
activation of p65 NFκB by casein kinase-II and typrosine kinase dependent pathways 
(Perkins, 2007).  
Growing evidence suggests a role for p65 NFκB during skeletal growth and 
development attributable to osteoblasts regulation. The expression of the p65 NFκB 
subunit is abundant while p50 and p52 subunits show lesser expression in growth plate 
of long bones where ossification occurs (Wu et al., 2007). Inhibition of p65 NFκB 
activity by specific NFκB inhibitors, PDTC and BAY, hampers longitudinal growth in 
rat metatarsal bone culture. In vitro activation of p65 mediated NFκB pathway by 
constitutively active IKKα promotes osteogenic differentiation of human 
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mesenchymal stem cells (Hess et al., 2009). However, the previous conclusions were 
based on indirect regulation of p65 NFκB function with redundant effects from other 
NFκB subunits. This present study demonstrates that p65 mediated NFκB activity is a 
critical factor in maintaining in vivo bone development and remodeling. Suppression 
of p65 NFκB activity impairs early osteoblast differentiation and survival of 
osteoprogenitor cells. 
Ikkα-/- mice have abnormal skeletal and craniofacial morphogenesis with 
delayed mineralization in palatal bones as accounted for unique function of Ikkα in 
epidermal differentiation (Hu et al., 1999; Li et al., 1999; Sil et al., 2004). In contrary, 
the current study demonstrated similar skeletal phenotypes but reflected direct effects 
of NFκB disruption on osteoprogenitors. Lack of one p65 allele affects bone 
development with impact on bone dimension and architecture. Skeletal staining of 
p65fl/+Osx-Cre mice exhibited osteopenic phenotype in longitudinal and craniofacial 
bone growth (Fig.2). Histological and µCT analysis revealed reduction of bone 
dimension as well as alteration of bone trabecular number in p65fl/+Osx-Cre mice 
(Fig.2E, Fig.3 and Table2). These bone phenotypes do not reflect nonspecific effect of 
Cre-recombinase enzyme in osteogenic cells as reported by indistinguishable microCT 
data between Osx-Cre mice and wild type controls from previous studies (Shimada et 
al., 2008). Indirect evidence of the effect of p65 mediated NFκB on skeletal growth 
was indicated with reduced size and lower weight in p65 haploinsufficient mice as 
compared with controls. A report regarding growth retardation with short stature in 
one patient identified a heterozygous mutation of IκBα gene which suggests the effect 
of impaired NFκB function in skeletal growth (Janssen et al., 2004).  
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The transactivational activity of NFκB is primarily attributed to the function of 
p65 subunit (Steinbrecher et al., 2008). Earlier studies indicated that p65 and p65/p50 
are transcriptional activators of Osx, a specific osteogenic regulator which implicated 
the role of p65 in osteoblast differentiation (Lu et al., 2006). The present study 
illustrates that the presence of one p65 allele failed to support sufficient p65 protein 
and activity, thereby affecting the osteogenesis process. In osteoinduced condition, 
osteoprogenitor cells lacking one p65 allele had 40% decrease of total p65 protein 
level in compared with the control counterparts (Fig.1D) which was concomitant with 
42% diminished NFκB transactivation activity (Fig.8A). Diminished NFκB activity 
from absence of one p65 allele impaired differentiation with less effect on 
proliferation. Osteogenic cells including MSCs and osteoprogenitor cells from 
p65fl/+Osx-Cre mice clearly presented impaired osteogenic potential. Markedly fewer 
CFU-OB in comparison with CFU-F of p65fl/+Osx-Cre MSCs implicated the role of 
NFκB in mesencymal stem cells differentiation. Less Alp activity with reduced 
mRNA abundance of selected ostegenic markers of p65fl/+Osx-Cre calvarial cells 
denoted impaired early differentiation in committed osteogenic cells. Differing 
evidence has been suggested in mice carrying defective Ikkɣ in early differentiated 
osteoblasts (Col1α1-IKK-DN) (Chang et al., 2009). Difference in bone phenotypes 
between p65fl/+Osx-Cre mice as described here and Col1α1-IKK-DN mice which 
exhibit enhanced bone formation may be attributed to residual activation of p65 NFκB 
from IKK independent pathway or from compensatory function of other NFκB 
subunits (Perkins, 2007; Shih et al., 2011; Steinbrecher et al., 2008). NFκB 
perturbation in terminally differentiated stage of osteoblasts provides differing results 
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in maintaining bone homeostasis, with increased osteoblast function in osteoporotic 
model of Bglap2-IKK-DN mice (Chang et al., 2009). Additional studies are essential 
to elucidate the function of p65 NFκB in bone homeostasis according to cell-and 
stage-specific characteristic. 
The other pivotal role of p65 NFκB is anti-apoptotic function (Beg et al., 1995; 
Steinbrecher et al., 2008). Mice devoid of p65 died in embryonic stage from severe 
liver apoptosis (Beg et al., 1995). Inhibition of p65 in chondrogenic cell line with 
PDTC, BAY, and p65 siRNA led to apoptotic mediated cell death as shown by 
upregulation of Bcl-2/Bax gene under caspase3 dependent pathway (Wu et al., 2007). 
Accumulating findings in our in vitro and in vivo experiments support a protective role 
of p65 NFκB in maintaining osteoblasts during normal physiological stage. Reduced 
caspase3/7 activity in osteoprogenitor lacking one p65 allele illustrated that p65 NFκB 
mediated anti-apoptotic function through caspase3/7 dependent pathway. 
Osteoprogenitors with reduced p65 NFκB activity had elevated apoptosis compared 
with controls in both normal and straurosporine challenged conditions. MSCs from 
p65fl/+Osx-Cre mice were affected from NFκB perturbation during osteoblast 
differentiation process. Decreased NFκB and increased apoptosis shift the skeletal 
balance to a reduced anabolic state. Decreased osteoblast survival may contribute to 
the observed phenotype in p65fl/+Osx-Cre mice. During bone destruction/injuries 
stage, reestablishement of new osteoblasts is required to counteract bone loss or 
resorption (Zaidi, 2007). Further work therefore is required to define the consequence 
of reduced p65 level on MSC and osteoprogenitor recruitment and survival during 
healing  and  regeneration  stage  in  order  to  find  optimal  condition   or   underlying  
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mechanism which support osteoblast activity in bone regeneration.  
A mechanistic basis for reduced skeletal growth in p65fl/+Osx-Cre mice may 
also include the lack of skeletal activators driven by NFκB. BMP2 is a key factor in 
skeletal development. BMP2 is well characterized and is an efficient inducer of 
RUNX2, a transcription activator controlling osteogenesis (Carter et al., 2008; King 
and Cochran, 2002; Lian and Stein, 2003; Matsubara et al., 2008). The promoter 
region of the Bmp2 gene contains two NFκB responsive elements where p65 and p50 
subunits interact with (Feng et al., 2003). Reduced p65 NFκB activity results in 
decreased Bmp2 mRNA expression in primary chondrocytes which interrupts 
metatarsal bone growth (Wu et al., 2007). Consistent with previous finding, 
p65fl/+Osx-Cre osteoprogenitor cells with reduced p65 NFκB activity exhibit less 
Bmp2 gene expression which may contribute to delayed bone formation presented in 
their skeletal phenotype and lower CFU-OB. This confirms a reduction in BMP2 
mRNA level following IKK/NFκB modulation in human mesenchymal stem cells 
(Hess et al., 2009). Alteration in Bmp2 induction with p65 and IκB overexpression in 
this study implicates a primary pathway that p65 mediates Bmp2 transcription through 
typical NFκB activity. Additionally, these results may describe the mechanism in 
which lack of one p65 allele causes delayed osteoblast development in our animals 
through abrogation of NFκB transcriptional activity on Bmp2 induction. Although 
inhibition of NFκB and its upstream regulators is considered as one factor in 
controlling the severity of inflammatory bone diseases (Chang et al., 2009), our result 
indicates that lack of NFκB mediated gene expression in osteoprogenitors negatively 
influences physiological bone formation process. It is possible that NFκB may 
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regulate other molecules to induce bone formation. Exploring the affected target genes 
from osteoprogenitor lacking on p65 allele will enable us to define signaling pathways 
that NFκB is involved during bone formation.  
In conclusion, a specific role of p65 NFκB in bone development is suggested 
by alteration of skeletal size and craniofacial development in mice with p65 
haploinsufficiency in osteoprogenitors. Disruption of p65 NFκB in osteoprogenitors 
causes detrimental effects in early stage of osteogenesis at multiple levels of 
regulation through differentiation and apoptosis protection. The osteogenic regulatory 
roles of p65 NFκB is mediated, at least in part, by Bmp2 induction. The role of p65 
NFκB on osteoblasts during bone repair and regeneration requires further examination.  
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 CHAPTER 3 
 
NFκB P65 MODULATES BONE FORMATION IN BMP2-INDUCED             
BONE REGENERATION  
 
Introduction 
Inflammatory regulation has emerged as a significant factor that determines 
bone regeneration outcome. Previous studies have demonstrated that several 
inflammatory mediators play essential roles in initial stages of bone 
repair/regeneration, while aberrant or chronic inflammation exacerbates detrimental 
effect in bone formation and bone remodeling as seen in rheumatoid arthritis or 
periodontitis (Mountziaris et al., 2011; Takayanagi, 2009).  Mice with chronic 
inflammation caused by long term exposure of TNFα exhibit rheumatoid arthritis-like 
condition which affects bone volume and strength (Alblowi et al., 2009). Abnormal 
elevated level of IL6 contributed to pathogenesis of polyarticular juvenile idiopathic 
arthritis with impaired osteoblast function (Caparbo et al., 2009). In contrast, mice 
with impaired Tnfα, Il6, and Cox2 have reduced bone regeneration potential with less 
mineralization due to compromised osteogenic response (Gerstenfeld et al., 2001; 
Yang et al., 2007; Zhang et al., 2002). Mice with nonfunctional Faslg display limited 
capability in rhBMP2 induced bone tissue engineering which is attributed to  
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suppressed Bsp, type I collagen and osteopontin mRNA levels (Katavic et al., 2003). 
In vitro evidences indicate positive roles of TNFα and IL6 in early stage of osteoblast 
development. In vitro short term stimulation of MSCs with TNFα and/or IL1β 
enhances osteogenic activities by promoting increase of early and late osteoblastic 
markers (Hess et al., 2009 Mountziaris et al., 2010). Preculture of preosteoblast 
MC3T3 cells with IL6 induces Runx2 and Ocn mRNA upregulation (Li et al., 2008). 
In recognition of the influence of inflammation on bone reconstruction, the molecular 
mechanism underlying this regulation remains unclear. 
 NFκB complexes represent the key inflammatory regulators based on their 
major role in innate and adaptive immunities (Li and Verma, 2002). NFκB is 
described as a dimeric transcription factor that is involved in activation and control of 
a variety of genes in response to cellular conditions (Perkins, 2007). Several lines of 
evidence suggest that NFκB pathway contribute to the control of inflammatory 
mediator-induced bone formation. The IKK/NFκB p65 pathway is indicated as an 
underlying mechanism in which TNFα stimulates bone formation in MSCs (Bocker et 
al., 2008; Crisostomo et al., 2008; Hess et al., 2009). In addition to TNFα, a potential 
inducer of NFκB activation, Fas ligand induces IL8 production by activating NFκB in 
a TNFα independent manner (Imamura et al., 2004). Additionally, several 
inflammatory mediators including COX2, PGE2, and IL6 showed to promote 
osteogenesis by acting on osteoblasts through the NFκB pathway (Chen et al., 2003; 
Fukuno et al., 2011; Jung et al., 2003).  
BMP2, a member of transforming growth factor-β superfamily, has been 
widely used in bone tissue engineering owing to its potent osteoinducing capacity 
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(Choi et al., 2002; Hou et al., 2007; Katayama et al., 2009; Triplett et al., 2009). The 
clinical outcomes of BMP2-induced bone regeneration are influenced by interplay 
among multiple factors including the implanted materials, the methods of BMP 
administration, and the host response which determines cellular activities attributed to 
bone formation process (Hu et al., 2010; Kim et al., 2005; Kim et al., 2011). The 
phenomenon of BMP2-mediated bone tissue engineering start from initial 
inflammation and cell migration, and continue with differentiation, bone replacement 
and remodeling of implanted materials (Hou et al., 2007). The association of an 
NFκB-mediated inflammatory response with osteoblast regulation during bone 
development as presented in chapter 2 suggests the potential effect of NFκB in bone 
regenerative outcome. To gain insight and understand the role of NFκB in 
osteogenesis during bone regeneration, the hypothesis was that NFκB modulates bone 
formation through osteoblast regulation in recombinant human BMP2-induced bone 
tissue engineering. 
Materials & method 
In vivo bone formation 
To further confirm the involvement of NFκB p65 in osteoblast differentiation 
in vivo, the bone formation capacity during bone regeneration process was stimulated 
by the implantation of collagen sponges containing 1 ug of recombinant human BMP2 
(rhBMP2) into subcutaneous tissues of cis-NFκB GFP mice (a kind gift from Dr. 
Christian Jobin from Lineburger Cancer Center, UNC), p65fl/+mice, p65fl/+Osx-Cre 
mice, and Osx-Cre mice. The collagen scaffolds and rhBMP2 were obtained from 
Infuse® Bone Graft kit (Medtronic, Minneapolis, MN). The collagen scaffolds were 
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prepared in a disk shape at 5 mm diameter using a tissue biopsy punch.  The rhBMP2 
or deionized water as a negative control was loaded into the scaffolds fifteen minutes 
prior to the implantation procedure. Recombinant human tumor necrosis factor alpha 
(TNFα) at 100 ng/ml concentration was also applied to some scaffolds as positive 
controls for NFκB activation analysis. Mice at five to seven weeks old of age were 
used. At least three mice from each group were used for each condition at each time 
point. The scaffolds were harvested at 3 days, 7 days, and 2 weeks after implantation 
in cis-NFκB GFP mice and at 2 weeks and 5 weeks after implantation in  p65fl/+, 
p65fl/+Osx-Cre and Osx-Cre mice. At least two independent experiments were 
performed. All experimental procedures have been approved by Institution Animal 
Care and Use Committee at the University of North Carolina at Chapel Hill and been 
in accordance with NIH animal handling procedures.   
For surgical procedures, the animals were anesthetized by intraperitoneal 
injection with a combination of 100 mg/kg ketamine and 5 mg/kg xylazine (PSS, West 
Columbia, SC). Following the preparation of the surgical site, a midlongitudinal skin 
incision at <1.5 cm in length was made at dorsal surface of each mice using a scalpel 
blade or scissors. Two to four subcutaneous pockets were created by blunt dissection 
per mouse and a single transplant was placed into each pocket. The surgical wound 
was closed with resorbable 4 or 5-0 chromic gut sutures (Ethicon, Somerville, NJ). 
The animals were sacrificed with carbon dioxide asphyxiation followed with cervical 
dislocation prior to the scaffold retrieval. The samples were fixed in 4% phosphate 
buffered paraformaldehyde for 24 hours and transferred to 70% ethanol before 
performing microcomputed tomographic, histological and immunohistochemical 
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analyses. In some samples, the scaffolds were divided into 2 pieces with a scalpel and 
were frozen in liquid nitrogen and stored at -80oC for RNA isolation and quantitative 
real-time PCR analysis.  
Microcomputed tomography (µCT)  
The images of mineralized structures from the collagen scaffolds retrieved 
from p65fl/+and p65fl/+Osx-Cre mice were acquired using a desktop microtomographic 
imaging system (Skyscan 1074HR, Aartselaar, Belgium) at a resolution of 20.5 
µm/pixel. Standardized scanning and image reconstruction settings were used. At least 
three specimens from each condition at each time point were imaged and assessed for 
the volume and quality of newly formed mineralized tissues. The measured parameters 
included bone mineral density (BMD) and bone volume fraction (BV/TV). Gray scale 
setting at 52 to 255 was used for bone volume and bone mineral density calculation. 
Hydroxyapatite phantoms (250 mg/cc and 750 mg/cc; CIRS, Inc., Norfold, VA) were 
used as references for bone mineral density (BMD) calculation. 
Histological evaluation 
After the scaffold samples were fixed in 4% phosphate-buffered 
paraformaldehyde and transferred into 70% ethanol, the samples were decalcified with 
0.2 mM Ethylenediamine-tetraacetic acid (EDTA, Sigma) at pH 7.4 in deionized water 
then dehydrated in descending ethanol series from 70%, 95% to 100% before a 
paraffin embedding procedure.  The tissue slides were obtained by serial sectioned 
cutting at 5-µm thickness. The sections were processed in a standard histological 
procedure and stained with hematoxylin-eosin for morphological examination or 
stained for other analyses. At least 6 representative sections from each implant were 
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evaluated and photographed under a light microscope (Nikon Eclipse50i, Nikon, 
Melville, NY). The slides from similar sections level were compared histological 
findings between the target and the control groups.  
RNA preparation and Quantitative real-time PCR  
In order to determine the mRNA expression patterns of osteogenic 
differentiation markers and NFκB pathway-related markers, the collagen scaffolds 
loaded with rhBMP2 or deionized water were harvested from the animals 2 weeks 
after subcutaneous implantation. The scaffolds were cut in half and total RNA was 
extracted from tissues formed in one-half piece of the scaffolds using TriZol reagent 
(Invitrogen, Carlsbad, CA) according to manufacturer protocol. Five hundred ng of the 
total RNA was reversed transcribed into first strand cDNA using the SuperScriptIII 
first-strand synthesis supermix for qRT-PCR kit (Invitrogen) in a 20-µl reaction 
volume. Quantitative real-time PCR was performed using the sequence specific 
primers and probes for osteogenic markers including Runx2 (Mm00501578_ml), Osx 
(Mm00504574_ml), Alp (Mm00475831_ml), Bsp (Mm00492555_ml), type I collagen 
alpha 1 chain (Col1A1; Mm00801666_g1), and osteocalcin (Bglap1; 
Mm_03413826_mH). The NFκB related molecules included p65 (Mm00501346_m1), 
nfkb1 (Mm00476361_m1), and Iκbα (Mm00477798_m1).  All reactions were 
amplified using Taqman Universal PCR Master Mix (Applied Biosystems, Foster 
City, CA) in ABI prism 7500 system.  Assays were performed in duplicate and the 
results were normalized to rodent Gapdh expression (ABI assay No. 4308313). The 
fold changes were calculated using the values obtained from the p65fl/+ animal group 
in the deionized water-loaded condition in as a calibrator then determined by means of 
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2-∆∆Ct method (Livak and Schmittgen, 2001).  For the comparison among groups in 
the rhBMP2-induced condition, the values from the p65fl/+ group with loaded rhBMP2 
were used as a calibrator. Statistical analyses were performed using an independent T-
test. 
Immunohistochemical staining  
The tissue sections from the paraffin embedded samples were processed by 
deparaffinization with xylene substitute (Hemo-D, Fisher) and rehydration using 
gradient ethanol. The antigens were retrieved with 10 mM sodium citrate buffer at 
70oC for 20 minutes. Endogenous hydrogen peroxidases in the tissues were quenched 
with 3% hydrogen peroxide in methanol followed by three rinses with phosphate 
buffered saline. The sections were incubated with 2.5% goat serum (Vector lab) 
diluted in 0.1% bovine serum albumin for 30 minutes at room temperature for 
nonspecific blocking. The sections were then blotted overnight at 40C with primary 
antibodies. After washed three times in PBS, the slides were incubated with a 
biotinylated secondary antibody for 45 minutes at room temperature. The antibody 
reaction was amplified and stained using an immunoperoxidase system by the 
incubation of the slides with the RTU ABC Elite reagents (Vector Laboratories, 
Burlingame, CA). The antibody complexes were visualized with a perioxidase 
substrate from DAB substrate kit (Vector Laboratories). The sections were 
counterstained with hematoxylin and processed for gradient dehydration before 
mounted with permount medium.  The primary antibodies included a rat monoclonal 
anti-F4/80 (Abcam, catalogue number ab6640) antibody at 1:200 dilution and a rabbit 
anti-bone sialoprotein antibody (a kind gift from Dr. Larry Fisher, NIH) at 1: 400 
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dilution. The secondary antibodies were goat anti-rat and goat anti-rabbit IgG 
antibodies (Vector Laboratories). The secondary antibodies were used at dilution of 
1:200 and 1:800 respectively.  Control sections were incubated with a nonspecific rat 
or rabbit IgG instead of the primary antibodies. Photographs of histological stained 
sections were captured under a Nikon Eclipse 50i microscope.  
Assessment of NFκB activation during rhBMP2-induced bone formation 
Enhanced green fluorescent protein (eGFP) representing NFκB activation was 
observed in the tissue sections from BMP2-loaded scaffolds from the cis-NFκB GFP 
mice.  The scaffolds were retrieved from the cis-NFκB GFP mice after 3 days, 7 days, 
and 14 days postimplantation. The scaffold samples were fixed in 4% 
paraformaldehyde for 10-24 hours then transferred to 70% ethanol before further 
processes. The samples were decalcified by 0.2 mM EDTA in deionized water, 
washed with tap water and transferred into 30% sucrose in phosphate buffered saline 
overnight. The samples were embedded in Tissue Tek® optimal cutting temperature 
compound (Sakura Finetek, Torrance, CA) and 5-µM sections were cut on a cryostat. 
After rinsing the sections with PBS for 5 minutes 2 times, the slide sections were 
soaked in 1 mM MgCl2 in PBS for 30 minutes and washed again with PBS for 5 
minutes. The sections were mounted in glycerol-based mounting medium before a 
microscopic analysis (Jiang et al., 2005). The eGFP expression was observed and 
images were captured using an inverted fluorescent microscope (Nikon Eclipse50i, 
Nikon, Melville, NY). After the fluorescent evaluation, some slide sections were 
counterstained with hematoxylin and photographed under the same microscope.   
Statistical analysis  
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The data were presented as mean with standard deviation. Statistical significant 
differences were determined using an independent Student’s t-test or non-parametric 
test. Statistical significance was defined at p-value less than 0.05.  
 
Result  
Effect of p65 haploinsufficiency in bone regeneration potential 
To evaluate changes in the bone formation potential as a result of p65 
haploinsufficiency, the heterotopic bone formation model was employed using BMP2-
mediated osteoinduction in this model. The capabilities of the target p65fl/+Osx-Cre 
and the control p65fl/+ mice to form mineralized tissues were assessed at 2 weeks and 5 
weeks postimplantation. MicroCT analysis of the transplants at both time points 
revealed no mineralization in the scaffolds without rhBMP2. The samples with 
rhBMP2 demonstrated small amount of calcified tissues at two weeks and more 
extensive mineralization at five weeks in both p65fl/+ and p65fl/+Osx-Cre groups. The 
mineralization was observed mainly at peripheral regions of the scaffolds. Although 
mineralized matrices were present in the rhBMP2-loaded transplants from the 
p65fl/+Osx-Cre group, quantification by microCT analysis indicated markedly lower 
mineralized tissue volume than those of controls (p<0.05) as demonstrated by bone 
volume per tissue volume ratio (Table 2). However, the mineralized tissue densities 
values of the mineralized scaffolds were comparable between the target p65fl/+Osx-Cre 
and the controls. 
Hematoxylin and eosin staining examination confirmed that the 
microstructures of the scaffolds delivering rhBMP2 from both target and control 
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animals contained newly formed mineralized tissues when rhBMP2 was applied. In 
contrary, the negative control scaffolds had only fibrous tissue ingrowth at both two- 
and five-week time points. Loose fibrous connective tissues with granulocytes were 
observed surrounding the scaffolds from both conditions. At 2 weeks, only the 
rhBMP2-loaded scaffolds from the control p65fl/+ mice displayed matrices representing 
woven bone structure at the periphery of the scaffolds. The rhBMP2-loaded scaffolds 
from the target p65fl/+Osx-cre mice showed less amount of the bone like structure with 
small nodules of mineralization (Fig.9). At 5 weeks in intact mice, the scaffolds 
containing rhBMP2 developed more bone like tissues in the presence of bone marrow 
compartments along with partial degradation of the collagen scaffolds.  The control 
group established intact cortical bone and trabecular structures with a large number of 
hematopoietic cells infiltrated into bone marrow region. The mineralized scaffolds 
from the target group showed less bony structures but displayed comparable bone 
marrow structure to the controls. Unorganized mineralized regions were observed in 
certain areas of the p65fl/+Osx-cre scaffolds. The residual scaffold materials remained 
visible in larger sizes than those from the controls (Fig.12). 
 Molecular characterization at gene expression levels was performed to 
determine the effect of p65 haploinsufficiency during the bone regeneration process 
from the transplanted scaffolds after 2-week implantation. The osteoblast 
differentiation and inflammatory activities were evaluated by quantifying the mRNA 
abundance of selected markers using quantitative real-time PCR (Fig. 10). The 
expression levels of all selected osteoblastic markers from all groups increased 
significantly upon rhBMP2 stimulation except Col1a1. The expression levels of these 
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markers were comparable between two control groups, the p65fl/+ and the Osx-Cre 
groups. Runx2 mRNA, a BMP2 target gene responsible for osteochondrogenic 
differentiation (Nakashima et al., 2002), demonstrated upregulation more than two 
times in response to the BMP2 osteogenic signal with comparable levels between the 
control p65fl/+ and the target p65fl/+OsxCre groups. In contrast, the expression levels of 
Osx, an osteogenic lineage specific marker, was significantly lower in the target group 
as compared with those in the controls. The levels of Alp and Bsp mRNA abundance 
were consistent with the Osx result as both genes are downstream targets of the Osx 
transcription factor (Matsubara et al., 2008). Change in Ocn mRNA abundance, a late 
maker of osteoblasts, confirmed the negative effect of p65 haploinsufficiency on 
osteoblast differentiation during the regeneration process with markedly lower 
expression level in the p65fl/+OsxCre group. These data indicated reduced osteoblast 
differentiation from cells migrating into the rhBMP2-loaded scaffolds of the 
p65fl/+OsxCre mice. This result resembles the previous result in the phenotype 
examination of the calvarial cells from p65fl/+OsxCre mice. However, the Col1A1 
mRNA demonstrated higher, although not statistical different, expression level in the 
target group. This may be relevant to the fibrous encapsulation at the scaffolds of the 
p65fl/+OsxCre group.  
 Previous studies have suggested that the inflammatory response has an 
important influence in bone repair and bone regeneration therapies (Mountziaris and 
Mikos, 2008; Mountziaris et al., 2011). Alteration of NFκB activity by targeting NFκB 
subunits expression or modulating IκB/NFκB complexes leads to change in 
inflammatory reaction via the effect on transcription control of cellular responses 
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(Shih et al., 2011). Therefore the mRNA abundance of p65, nfkb1 which encodes 
p105/p50, and Iκbα was measured in cells from the harvested scaffolds as presented in 
Figure 11. The mRNA levels of these NFκB related genes, specifically Iκbα, in the 
control group revealed suppression following rhBMP2 stimulation after 2 weeks 
whereas the expression levels of these genes elevated in the target group, especially 
the p65 level, which was higher than the control at the non-stimulated condition. In 
rhBMP2-induced conditions, Iκbα mRNA levels from the p65fl/+OsxCre group showed 
significantly higher levels than the p65fl/+ control group, implicating difference of 
NFκB activity as a consequence of p65 haploinsufficiency.  
 To further assess the profile of newly formed tissues in the osteoinduced 
scaffolds, immunohistochemistry was used to determine the population of active 
osteogenic cells and mature macrophages which were responsible for bone 
replacement in the scaffold material. Bsp is an essential molecule for active 
osteoblasts (Ganss et al., 1999). F4/80 serves as a marker for functioned macrophages 
but not osteoclasts (Chang et al., 2008). Therefore immunostaining was performed 
using antibodies against Bsp and F4/80 in this study. Haploinsufficiency of p65 in 
osteoprogenitors revealed retarded bone formation in the scaffolds with fewer Bsp 
positive cells and less F4/80 positive macrophages which played a role in scaffold 
matrices degradation. In contrast, the control group illustrated several areas with 
osteogenic cells and large population of macrophages surrounding the collagen 
scaffolds (Fig. 13 and 14).   
cis-NFκB EGFP expression exhibits temporal and spatial pattern of NFκB 
activation during bone formation 
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To define the association between NFκB activitiy and bone formation in vivo, 
the cis-NFκB EGFP reporter mice were used as a tool to monitor the kinetics of NFκB 
activation following BMP2-mediated osteoinduction. Frozen sections of the scaffolds 
disected from the cis-NFκB EGFP reporter mice were examined for eGFP expression 
under a fluorescent microscope (Fig. 15). The eGFP emission representing NFκB 
activation exhibited the strongest intensity in the TNFα-loaded group at day 3 then 
decreased gradually from day 7 to day 14. The deionized water-loaded group which 
served as a negative control showed slightly expression of eGFP only in day 3, 
reflecting an inflammatory response from a surgical procedure.  The addition of 
rhBMP2 resulted in different eGFP expression patterns with low intensity at day 3. 
Although sparsely, increased cis-NFκB EGFP positive cells were observed at day 7 
and day 14 respectively. The same sections from rhBMP2 samples at day 14 were 
counterstained by hematoxylin to localize morphological structures in the scaffolds. 
The cis-NFκB EGFP positive cells were visualized in the area next to newly formed 
bone tissues. The result from this experiment implicated NFκB involvement during 
BMP2-mediated osteogenesis. 
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Table3 µCT analysis of rhBMP2-induced scaffolds from p65fl/+ and p65fl/+Osx-Cre 
mice 
Measurement
Week 2 Week 5
p65fl/+ p65fl/+Osx-Cre p65fl/+ p65fl/+Osx-Cre
Percent bone 
volume 11.726+3.36 1.443+0.68* 16.955+5.54 2.999+1.71*
Bone mineral 
density (g/cm3)
0.087+0.030 0.053+0.021 0.205+0.023 0.192+0.035
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*p<0.05 versus p65fl/+, n = 4-5 per group 
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Figure 9 Hematoxylin and eosin staining of sections from 2-week implanted 
scaffolds. A) Paraffin-embedded sections of representative implanted scaffolds harvested 
from p65fl/+ and p65fl/+Osx-Cre mice. Upper panel displayed different morphology of the 
scaffolds from each condition. Scale bars indicate 200 µM. Lower panel demonstrated 
magnification of the structure of the peripheral region of the scaffolds. The scaffolds without 
rhBMP2 contained surrounding fibrous tissues whereas those with rhBMP2 displayed bone-
like structure with less amount in the p65fl/+Osx-Cre group. Scale bars indicate 10 µM. N=3 
animals per group per condition B) Representative sections of the rhBMP2 loaded scaffolds 
retrieved from the Osx-Cre mice. Scale bars indicate 10 µM. N=2 animals.  
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Figure 10 mRNA expression profiles of osteoblastic markers. The expression levels 
of osteoblastic markers from the dissected scaffolds demonstrated reduced osteogenic 
potential in p65fl/+Osx-Cre mice. Relative expression levels of osteoblastic gene markers after 
14 days post-implantation in p65fl/+ and p65fl/+Osx-Cre mice were assessed by realtime PCR 
for Runx2, Osx, Alp, Bsp, Col1a1, and Ocn. n=4 animals per group/condition. Data are shown 
as mean + SD. *, p<0.05 versus p65fl/+ in condition without BMP2. #, p<0.05 represents 
difference between the p65fl/+Osx-Cre versus the p65fl/+ groups in BMP2 condition. The 
experiment was performed in duplicate.  
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Figure 11 mRNA expression profiles of NFκB pathway related molecules. Relative 
expression levels of NFκB related molecules from the scaffolds after 14 days post-
implantation in p65fl/+ and p65fl/+Osx-Cre mice were assessed by realtime PCR for p65, nfkb1, 
and Iκbα n=4 animals per group/condition. Data are shown as mean + SD. *, p<0.05 versus 
p65fl/+ in condition without BMP2. #, p<0.05 represents difference between p65fl/+Osx-Cre 
versus p65fl/+ group in BMP2 condition. The experiment was performed in duplicate. 
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Figure 12 Hematoxylin and eosin staining of sections from 5-week implanted 
scaffolds. A), B) Paraffin embedded sections of the representative rhBMP2-loaded scaffolds 
harvested from two different p65fl/+ and C), D) p65fl/+Osx-Cre mice. Upper panel displayed 
overall morphology of the scaffolds from each condition. Scale bars indicate 200 µM. Middle 
panel displayed structures at the peripheral regions of the scaffolds. Scale bars indicate 100 
µM. Lower panel demonstrated magnification of the structure at mineralized-bone marrow 
junctions inside the scaffolds. Scale bars indicate 10 µM. N=4 animals per group per 
condition.  
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Figure 13 Immunostaining of Bsp in 5-week mineralized scaffolds. A) Bsp 
immunohistochemical staining of paraffin embedded sections of the representative scaffolds 
harvested from p65fl/+ and B) p65fl/+Osx-Cre mice. C) IgG control for Bsp 
immunohistochemical staining of sections of the scaffolds from p65fl/+ and D) p65fl/+Osx-Cre 
mice. Scale bar indicates 10 µM.  
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Figure 14 Immunostaining of F4/80 in 5-week mineralized scaffolds. A) F4/80 
immunohistochemical staining of paraffin embedded sections of the representative scaffolds 
harvested from p65fl/+ and B) p65fl/+Osx-Cre mice. C) IgG control for F4/80 
immunohistochemical staining of sections of the scaffolds from p65fl/+ and D) p65fl/+Osx-Cre 
mice. Scale bar indicates 200 µM.        
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Figure 15 Kinetics of NFκB activation in early stage of bone regeneration. 
Enhanced GFP expression was visualized in the sections of harvested scaffolds from cis-
NFκB EGFP mice. The sections represented the scaffolds pretreated with A) 100 ng of TNFα, 
B) 1µg of rhBMP2, and C) deionized water from day 3, 7, and 14. Scale bar indicates 200 µM. 
D) The eGFP positive cells were located in the area adjacent to newly formed bone-like 
structure in the rhBMP2-loaded scaffolds retrieved at day 14 postimplantation. E) 
Hematoxylin counterstained of D). Slide sections displayed localization and morphology of 
bone-like structures in the scaffolds. Scale bars in D) and E) indicate 10 µM. N=3 animals per 
group. 
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Discussion 
NFκB strongly correlates with the initiation and the resolution of diseases of an 
inflammatory origin due to its profound function in inflammatory gene regulation 
(Lawrence et al., 2005; Perkins and Gilmore, 2006). Modulation of NFκB activity 
becomes an attractive target for defining pathogenesis and therapeutic strategies in 
several inflammatory diseases (Karrasch et al., 2007; Lippert et al., 2009; Steinbrecher 
et al., 2008). In accordance with the pivotal roles of NFκB in inflammatory regulation, 
the present study supports the importance of initial inflammatory phase in bone 
repair/regeneration. In vitro evidence demonstrates a stimulatory effect of TNFα in 
hMSCs as related to osteogenesis through a p65-mediated NFκB pathway (Bocker et 
al., 2008; Crisostomo et al., 2008; Hess et al., 2009). Absence of Tnfα signaling 
impairs bone repair/regeneration potential in a murine fracture model (Gerstenfeld et 
al., 2001; Gerstenfeld et al., 2003). Mice lacking downstream NFκB targets such as 
Cox2 and Il6 show delayed bone healing resembling the outcome in TNFα recepter 
p55/p75 target deletion mice (Appleby et al., 1994; Libermann and Baltimore, 1990; 
Simon et al., 2002; Yang et al., 2007; Zhang et al., 2002). Pharmacological COX2 
inhibition for 5-7 days immediately after bone fracture interferes with the 
inflammatory phase of the healing process which leads to disruption of newly formed 
bone as shown by less bone mineral density or high prevalence of osseous nonunion 
(Dimmen et al., 2009). Conversely, stimulation of inflammation during early bone 
healing phase enhanced the bone regeneration outcome. Local administration of TNFα 
at the beginning stage of bone injury accelerates mineralization after 4 weeks (Glass et 
al., 2011). Similar results were observed in murine bone fracture healing with short 
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term exposure of IL1β, or IL6 immediately after bone injury (Ding et al., 2009; Rozen 
et al., 2007). The role of in NFκB in ectopic bone formation demonstrates a direct 
effect of NFκB signaling in osteoblastic cells recruited to scaffolds by rhBMP2 in 
tissue engineering.    
The aim of this study was to investigate the relationship between NFκB and 
bone formation occurring in rhBMP2-mediated tissue engineering. Therapy using 
rhBMP2 has been considered as an effective approach to promote bone repair and 
regeneration according to its capability to promote cell migration, differentiation, and 
bone formation (Kim et al., 2005; Kimura et al., 2010). Despite the transcriptional role 
of NFκB in BMP2 during bone development was identified (Feng et al., 2003), the 
effect of NFκB in exogenous BMP2-induced bone regeneration remains inconclusive. 
The results of phenotype characterization of p65fl/+Osx-Cre mice as described in 
chapter 2 indicate that NFκB p65 modulates bone development through osteoblast 
regulation in perspective of differentiation control and protective role in apoptosis. In 
this study, bone regeneration potential in p65fl/+Osx-Cre mice was evaluated to define 
the role of NFκB in an early stage of bone formation in BMP2 delivery system. 
The major findings in this study indicated that NFκB p65 regulates BMP2-
mediated bone formation by direct modulation of osteoblast differentiation in vivo. 
Osteogenic response in the control mice p65fl/+ with normal NFκB activity appeared in 
a typical pattern of mesenchymal cell infiltration, differentiation, new bone formation 
in the first 2 weeks then followed with remodeling of the scaffolds and incorporation 
of hemotopoietic bone marrow at 5 weeks (Fig. 9 and 12). Reduced amount of newly 
formed bone from H&E staining was observed in the mineralized scaffolds dissected 
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from p65fl/+Osx-Cre mice as early of 2 weeks following BMP2 delivery and remained 
in the later remodeling stage at 5 weeks. In addition to the histological findings, the 
microCT assessment confirmed reduced bone formation in p65fl/+Osx-Cre mice with 
apparent smaller mineralized tissue volume in the BMP2-loaded scaffolds. The 
involvement of NFκB during bone formation was delineated with the cis-NFκB GFP 
mice which are a valid model for monitoring in vivo NFκB activation (Magness et al., 
2004). Induction of cis-NFκB GFP transgene represented dynamic of NFκB activity in 
response to BMP2 stimulation. NFκB activation appeared in later stages at day 7 and 
day 14 which concurred with bone formation process (Fig. 15). Additionally, cells 
with activated NFκB were localized next to newly formed bone tissues, implicating 
the cells responsible for bone formation. Immunohistochemistry in p65fl/+ and 
p65fl/+Osx-Cre samples indicated that prominent population of cells located next to 
bone tissue were Bsp positive which corresponded to active osteblastic cells (Hunter 
and Goldberg, 1994).  These findings exemplified the correlation of NFκB in 
osteogenic cells.  
The molecular mechanism of BMP2-induced osteoblast differentiation 
involves sequential activation of Runx2 and Osx transcription factors which play a 
role as key stimulators of molecules essential for bone tissue formation Col1a1, Alp, 
Bsp, and Ocn (Balint et al., 2003; Chen et al., 1997; Matsubara et al., 2008). The 
change in osteogenic gene expression profiles of the scaffolds from p65fl/+Osx-Cre 
mice in the present study suggested that the mechanism in which NFκB modulated 
osteogenesis in a BMP2-mediated regeneration process contributed to its regulatory 
roles on osteoblast differentiation. Upregulation of Runx2 mRNA, an essential 
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osteochondrogenic transcription factor (Komori et al., 1997) occurred in response to 
rhBMP2 at comparable levels between target and control groups whereas the 
expression levels of other downstream specific osteogenic markers Osx, Bsp, Alp, and 
Ocn significantly decreased in p65fl/+Osx-Cre mice. NFκB may have a selective role in 
control of osteogenesis; Runx2 levels were not affected in a dramatic way by the 
targeted deletion of p65. Although Osx expression has been shown to be highly 
relevant to Runx2 (Nakashima et al., 2002), the transcriptional activation of Osx is 
under distinct regulation. BMP2-mediated Osx expression is induced by two distinct 
pathways through Runx2 and Msx2 regulation. Runx2 positively influences Osx 
mRNA transcription through Smad1/4 signaling upon BMP2 osteinduction. Runx2 
deficient mesenchymal cells reveal the role of Msx2 in Osx with elevated Osx 
expression upon Msx2 overexpression. Knockdown of Msx2 leads to reversion of the 
outcome with suppression of the Osx level (Matsubara et al., 2008).  
Another explanation is based on NFκB transcriptional role in Osx specifically 
to p65 mediated pathway. The existence of NFκB binding site in Osx promoter was 
demonstrated by Osx promoter-mediated luciferase expression by p65 and p65/p50 
constructs (Lu et al., 2006). Reduced level of Osx derived from the mineralized 
scaffolds of the p65fl/+Osx-Cre mice may represent as a consequence of lower NFκB 
p65 level in osteoblasts. The consistent reduction of Alp, Bsp, and Ocn mRNA 
abundance (Fig. 10) indicated downstream effect of lower Osx expression on 
osteoblast phenotypes since these osteogenic markers are regulated by the presence of 
the Osx (Matsubara et al., 2008).  
The  apparent change  of  Bsp  gene expression may be due to a combination of 
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downstream effect from Osx and direct effect of NFκB on Bsp transcription. The 
promoter region of Bsp gene contains one κB binding site close to TATA box 
sequence which plays important role in Bsp transcription (Sodek et al., 1996). To 
better understand the role of NFκB in controlling mesenchymal cell differentiation 
during bone regeneration, complete gene profiles remain to be clarified. 
Comparable osteogenic gene expression levels of the p65fl/+ and the Osx-Cre 
mice confirmed that perturbation of osteoblast development was not an indirect 
consequence of the Cre-recombinase existence. This result indicated reduced 
osteoblast differentiation from cells migrating into the scaffolds of the conditional 
osteoblast-specific p65 haploinsufficient mice. These data demonstrated similar effect 
on osteogenesis as shown in the in vitro phenotype in chapter 2, illustrating that p65 
mediated NFκB pathway is critical in osteogenesis in both development and 
regeneration processes.  
 Previous evidence has indicated the significance of balance in basal levels of 
each NFκB subunit on NFκB activity (Hoffmann et al., 2003; Steinbrecher et al., 
2008). The function of p65 mediated NFκB is tightly regulated through IκB/NFκB 
complexes (Hoffmann et al., 2002). To better understand the compensatory response 
of NFκB activity in p65 haploinsufficiency in osteoblasts, this study therefore assessed 
the alteration of expression levels of NFκB related molecules including p65, nfkb1, 
and Iκbα. Despite the p65 and nfkb1 mRNA levels in p65fl/+Osx-Cre mice were not 
significantly different from the controls, increased Iκbα mRNA level was noted in 
p65fl/+Osx-Cre mice during bone formation (Fig. 11). The major function of Iκbα is to 
inhibit  NFκB  activation  by  coordination  with  other  members  of  IκB  proteins   to 
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sequester NFκB in the cytoplasm (Hoffmann et al., 2002; Tergaonkar et al., 2005).  
It is plausible that different cell population inhabited in the scaffolds of the 
control and target groups. The rhBMP2-loaded scaffolds from p65fl/+Osx-Cre group 
may have fewer osteogenic cells but more of other cells types which contain fully 
functioned NFkB activity. Additionally, less osteogenic cells in the target mice may 
lead to alteration in wound healing process. Data from immunostaining of F/40 
positive cells suggested change in healing process with fewer amount of F/40, marked 
as macrophages, in the target mice together with larger remaining scaffold matrices 
(Fig. 14). The delayed tissue/scaffold remodeling suggested that osteoblasts may play 
a role in recruiting macrophages in the bone regeneration process. Taken together, p65 
haploinsufficiency in osteoblast resulted in delayed bone regeneration at both 
differentiation and remodeling stages. However, the mechanism in which NFκB 
affects osteoblast functions during bone regeneration requires further examination.  
In conclusion, the present study demonstrates the direct effect of NFκB p65 in 
tissue-engineering-based bone formation. Lack of one p65 single allele significantly 
retarded in vivo bone formation in BMP2-delivery system in regard to osteoblast 
differentiation control. Kinetics of NFκB activation during bone regeneration 
indicated the interplay between inflammatory response and process of new tissues 
formation. Together this study provides basic knowledge concerning inflammatory 
regulation that can impact clinical outcome of bone tissue engineering. 
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CHAPTER 4 
 
DISCUSSION 
 
Osteogenesis is a series of complicated bone formation processes that occur 
during developmental and postnatal stages under multifactorial control of various factors 
and microenvironment. The physiological maintenance of bone requires bone formation 
which is established by regulated osteoblast development and function from 
mesenchymal stem cells. Osteogenesis, the bone formation process, involves segregable 
cellular phases including proliferation, differentiation, bone matrix synthesis, and 
mineralization (Neve et al., 2011). Determination of cell fate in osteoblast development is 
meticulously regulated by extrinsic factors in association with intrinsic responses. 
Extrinsic regulation of cell fate encompasses components of the microenvironment where 
a source of osteogenic cells resides including soluble factors, cell-cell communication 
and cell-extracellular matrix interaction. Intrinsic regulation including transcription 
factors, transmembrane or intracellular proteins, and chromosomal modification together 
converge to influence cellular behaviors in response to extracellular microenvironments 
(Long, 2011).    
NFκB provides a comprehensive role in developmental and diseased states as part 
of intrinsic regulation of cell fate which leads to the transformation of extrinsic factors. In 
the  context  of  bone pathophysiology,  aberrant  activation  of  NFκB  induces osteoclast 
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differentiation and resorption activity through the RANKL dependent pathway (Novack, 
2011). NFκB activation also leads to production of inflammatory cytokines such as 
TNFα, IL1, IL6, IL8 resulting in recruitment of immune cells which in turn secrete these 
cytokines, thereby promoting persistent NFκB activation (Li and Verma, 2002). 
Functional roles of NFκB in perspective of bone development are paradoxical to bone 
pathogenesis in regard to requisite concern on initiation of osseous wound healing and 
stimulatory effect on mesenchymal stem cell differentiation (Crisostomo et al., 2008; 
Kon et al., 2001; Mountziaris et al., 2011; Rundle et al., 2006). Ablation of inflammatory 
mediators that tightly associate with the NFκB pathway, such as TNFα, Cox2, by either 
genetic or pharmacological manipulation causes bone growth and regeneration 
retardation due to reduced bone formation capacity (Gerstenfeld et al., 2001; Gerstenfeld 
et al., 2003; Li et al., 2007; Simon and O'Connor, 2007; Zhang et al., 2002) Enhancing 
inflammation at the beginning of bone healing by administration of TNFα promotes bone 
formation at the fracture site (Glass et al., 2011). The promoting effect of TNFα on bone 
formation has been partially clarified the involvement of NFκB regulation on osteoblast 
differentiation (Hess et al., 2009).   
The aim of this study was to gain more insights into the direct influence of NFκB 
in osteoblast development which ultimately affected bone homeostasis concerning 
osteogenesis processes. By employing the genetic manipulating approach, mice with 
deletion of NFκB p65 single allele in osteoprogenitors, p65fl/+Osx-Cre, have been used to 
decipher the regulatory role of NFκB on an early stage of osteoblast development during 
initial skeletal growth and bone regeneration. The association of NFκB and bone 
development was investigated in the cis-NFκB EGFP reporter mice, an in vivo model for 
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NFκB activation analyses (Magness et al., 2004). The bone phenotypes of p65fl/+Osx-Cre 
mice from physiological and BMP2-induced conditions suggested that NFκB is required 
for both normal skeletal development and bone regeneration. The parallel BMP2 
induction experiment in cis-NFκB EGFP mice implicated direct association of NFκB 
signaling in the early stage of bone formation. 
Previous studies highlighted the significance of NFκB in endochondral 
ossification through BMP2-mediated chondrocyte promotion (Feng et al., 2003; Wu et 
al., 2007). In this study, the results from differentiation assays in Chapter 2 and 3 
illustrated that NFκB involves direct regulation of osteoblastic markers expression. 
Reduced BMP2 mRNA abundance in calvarial cells with p65 haploinsufficiency 
suggested that BMP2 is also involved in intramembranous bone formation under NFκB 
regulation. Osteocalcin is a specific marker for mature cells in osteoblastic lineage (Neve 
et al., 2011). Upregulation of osteocalcin mRNA in the control animals and significant 
expression reduction of this gene in p65fl/+Osx-Cre mice in BMP2-mediated ectopic bone 
formation clearly indicated that BMP2 directly participates in the NFκB-regulated 
osteoblast differentiation mechanism. Markedly decreased levels other osteoblastic gene 
markers, Osx, Alp, and Bsp, in BMP2-induced bone formation verified the critical role of 
NFκB in early bone regeneration process. 
In addition to direct BMP2 and Osx gene regulation (Feng et al., 2003; Lu et al., 
2006), a potential role of NFκB in the regulation of other ostegenic transcription factors 
has been suggested. Previous findings demonstrated that NFκB mediated Msh homeobox 
homologue 1 (Msx1) gene expression which contained three κB binding sites in the 
promoter region (Bushdid et al., 2001). Msx1 is a homeobox-containing transcription 
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factor which strongly expressed in developing craniofacial bones. Mutation of Msx1 
causes failure in tooth formation and non-syndromic cleft palate in human and mice 
(Alappat et al., 2003). Msx1 deficient mice also display middle ear defects from impaired 
malleus bones formation (Satokata and Maas, 1994). The diverse functions of NFκB in 
site-specific bone development need further investigation. 
Differences of CFU-F and CFU-OB result from p65fl/+Osx-Cre bone marrow cells 
suggested the relationship between NFκB and stem cell specification. NFκB effect on 
mesenchymal stem cells differentiation in this study is consistent to previous evidences 
that demonstrated differential induction effect of NFκB/IKK system on human 
mesenchymal stem cells (Hess et al., 2009). Mesenchymal stem cells are attractive target 
for bone regeneration therapy. Mechanisms in which NFκB control mesenchymal cell 
behaviors should be considered in an effort to better understand the management of stem 
cell biology for clinical improvement in bone regeneration/repair. 
In addition to differential regulation, the protective role of NFκB in apoptosis was 
reiterated in this study. Profound effects of NFκB p65 in anti-apoptosis have been stated 
in several studies (Beg et al., 1995; Geisler et al., 2007; Rosenfeld et al., 2000; 
Steinbrecher et al., 2008). In osteoclasts, p65 provides protective role against apoptosis 
during osteoclastogenesis (Vaira et al., 2008). Successful osteogenesis requires sufficient 
number of osteogenic cells especially in bone defects with compromised healing 
potential. Understanding this function of NFκB may be beneficial to application in stem 
cell engraftment in bone tissue engineering therapy.    
In conclusion, this project has contributed to the understanding of NFκB function 
in  early  stages  of  osteogeneis.  Haploinsufficiency  of  NFκB  p65  in  osteoprogenitors 
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impacts bone formation potential at multiple levels of regulation thereby affecting bone                
homeostasis.  
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